var title_f3_53_3920="Intraabdominal free fluid Morisons pouch";
var content_f3_53_3920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/59280/Intraabd_Moris_pouch_movie.mp4?title=Intraabdominal+free+fluid+Morisons+pouch\" style=\"width:496px;height:320px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Intraabdominal free fluid at Morisons pouch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This video clip taken from a FAST examination shows free fluid in Morisons pouch (between the liver and right kidney).",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3920=[""].join("\n");
var outline_f3_53_3920=null;
var title_f3_53_3921="Tracheal bronchus I";
var content_f3_53_3921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheal bronchus, also called pig bronchus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A contrast tracheobronchogram shows an accessory right upper lobe bronchus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3921=[""].join("\n");
var outline_f3_53_3921=null;
var title_f3_53_3922="Chapter 8D: Volume regulation versus osmoregulation";
var content_f3_53_3922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 8D: Volume regulation versus osmoregulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3922/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3922/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3922/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3922/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3922/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/53/3922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This chapter has dealt with the factors involved in the maintenance of the effective circulating volume. It is important, however, to be aware that these homeostatic mechanisms are very different from those involved in the maintenance of the plasma osmolality (",
"    <a class=\"graphic graphic_table graphicRef51153 \" href=\"UTD.htm?22/41/23195\">",
"     table 1",
"    </a>",
"    ). The plasma osmolality is determined by the ratio of solutes (primarily Na+ and K+ salts) and water, whereas the extracellular volume is determined by the absolute amounts of Na+ and water that are present. A few simple examples can illustrate the difference between these parameters.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exercising on a hot day leads to the loss of dilute fluid as sweat. The net effect is a",
"      <strong>",
"       rise",
"      </strong>",
"      in the plasma osmolality and Na+ concentration, but a",
"      <strong>",
"       fall",
"      </strong>",
"      in the extracellular volume. Similar changes can be seen in a nursing home patient who develops viral gastroenteritis, characterized by fever, profuse diarrhea, and decreased fluid intake.",
"     </li>",
"     <li>",
"      An infusion of isotonic saline will cause volume expansion, with no alteration in the plasma osmolality.",
"     </li>",
"     <li>",
"      The administration of one-half isotonic saline will initially lower the plasma sodium concentration by dilution and raise the extracellular fluid volume.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Changes in the plasma osmolality, which is primarily determined by the plasma Na+ concentration, are sensed by osmoreceptors in the hypothalamus (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    ). These receptors affect both water intake and water excretion by influencing thirst and the release of antidiuretic hormone (ADH), respectively (",
"    <a class=\"graphic graphic_table graphicRef51153 \" href=\"UTD.htm?22/41/23195\">",
"     table 1",
"    </a>",
"    ). The latter increases the urine osmolality and causes water retention by enhancing the permeability of the collecting tubules to water. Notice that osmoregulation is achieved by alterations in",
"    <strong>",
"     water balance",
"    </strong>",
"    ; Na+ handling is not directly affected unless there are concurrent changes in volume. Although it is tempting to assume that regulation of the plasma Na+ concentration has something to do with Na+, it is actually water intake and excretion that are affected.",
"   </p>",
"   <p>",
"    Volume regulation, on the other hand, attempts to maintain tissue perfusion. Different sensors and effectors are involved in this process, as it is urinary Na+ excretion, not osmolality, that is primarily modified (",
"    <a class=\"graphic graphic_table graphicRef51153 \" href=\"UTD.htm?22/41/23195\">",
"     table 1",
"    </a>",
"    ). The only major area of overlap involves the hypovolemic stimulus to ADH release; the ensuing water retention will then help to restore normovolemia.",
"   </p>",
"   <p>",
"    The independent roles of the osmoregulatory and volume regulatory pathways can be appreciated by returning to the examples described above.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The rise in plasma osmolality following exercise on a hot day will stimulate both ADH release and thirst; the ensuing increase in urine osmolality and subsequent water retention will eventually return the plasma Na+ concentration toward normal. This subject is also volume depleted; consequently, there will be activation of the renin-angiotensin-aldosterone system, resulting in a fall in urinary Na+ excretion. The net effect is that the urine will initially be highly concentrated and contain relatively little Na+.",
"     </li>",
"     <li>",
"      Similar hormonal changes occur in the nursing home patient with gastroenteritis. However, the degree of extracellular fluid volume depletion is likely to be greater due to salt loss in the diarrheal fluid.",
"     </li>",
"     <li>",
"      ADH release and thirst are not altered with an infusion of isotonic saline, since there is no change in the plasma osmolality. In this setting, only volume regulation is activated as the associated volume expansion diminishes the release of aldosterone and increases that of ANP. The net effect is excretion of the excess Na+ and water in a relatively isosmotic urine.",
"     </li>",
"     <li>",
"      Half-isotonic saline causes both hypoosmolality and volume expansion. Thus, ADH and renin release will be reduced and ANP secretion enhanced, thereby allowing the excess NaCl to be excreted in an appropriately dilute fluid. Thus, the person who exercises on a hot day is dehydrated with a small degree of volume depletion, the nursing home patient with gastroenteritis is also dehydrated with a greater degree of volume depletion, and a patient with diarrhea who maintains a normal plasma Na+ concentration is volume depleted but not dehydrated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28017391\">",
"    <span class=\"h1\">",
"     DEHYDRATION VERSUS VOLUME DEPLETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations permit an understanding between two terms that are often used synonymously but actually refer to different phenomena: dehydration and volume depletion (also called hypovolemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3922/abstract/1\">",
"     1",
"    </a>",
"    ]. Dehydration refers to water loss that leads to an elevation in plasma sodium concentration and an intracellular water deficit due to the osmotic movement of water from the cells into the extracellular fluid. In comparison, volume depletion refers to an decline in the extracellular fluid volume due to the loss of sodium and water. It can be produced by salt and water loss (as with vomiting, diarrhea, diuretics, bleeding, or third space sequestration) or by water loss alone (ie, dehydration).",
"   </p>",
"   <p>",
"    This text is continued separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17875?source=see_link\">",
"     \"Chapter 9A: Water balance and regulation of plasma osmolality\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3922/abstract/1\">",
"      Mange K, Matsuura D, Cizman B, et al. Language guiding therapy: the case of dehydration versus volume depletion. Ann Intern Med 1997; 127:848.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7271 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3922=[""].join("\n");
var outline_f3_53_3922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28017391\">",
"      DEHYDRATION VERSUS VOLUME DEPLETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7271\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7271|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/41/23195\" title=\"table 1\">",
"      Osmoregulation v volume reg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17875?source=related_link\">",
"      Chapter 9A: Water balance and regulation of plasma osmolality",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_53_3923="Patient information: Health risks of obesity (The Basics)";
var content_f3_53_3923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83815\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/3/3125\">",
"         Your body mass index (BMI)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/30/23010\">",
"         Patient information: My child is overweight (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/25/15763\">",
"         Patient information: Preventing type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/31/14835\">",
"         Patient information: Weight loss surgery (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/22/9572\">",
"         Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/37/9811\">",
"         Patient information: Weight loss surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33876\">",
"         Patient information: Weight loss treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Health risks of obesity (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/health-risks-of-obesity-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1674119769\">",
"      <span class=\"h1\">",
"       What does it mean to be obese?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors use a special measure called &ldquo;body mass index,&rdquo; or BMI, to decide who is underweight, at a healthy weight, overweight, or obese. A person who is obese weighs way too much for his or her height.",
"     </p>",
"     <p>",
"      Your BMI will tell you whether your weight is appropriate for your height (",
"      <a class=\"graphic graphic_figure graphicRef62886 \" href=\"UTD.htm?3/3/3125\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        If your BMI is between 25 and 29.9, you are overweight.",
"       </li>",
"       <li>",
"        If your BMI is 30 or greater, you are obese.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Being obese is a problem, because it increases the risks of many different health problems. It can also make it hard for you to move, breathe, and do other things that people who are at a healthy weight can do easily. Plus, being obese can be hard emotionally, because it can make you feel ashamed or like you don&rsquo;t fit in.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119784\">",
"      <span class=\"h1\">",
"       What are the health risks of being obese?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Being obese increases a person&rsquo;s risk of developing many health problems. Here are just a few examples:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diabetes",
"       </li>",
"       <li>",
"        High blood pressure",
"       </li>",
"       <li>",
"        High cholesterol",
"       </li>",
"       <li>",
"        Heart disease (including heart attacks)",
"       </li>",
"       <li>",
"        Stroke",
"       </li>",
"       <li>",
"        Sleep apnea (a disorder in which you stop breathing for short periods while asleep)",
"       </li>",
"       <li>",
"        Asthma",
"       </li>",
"       <li>",
"        Cancer",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119799\">",
"      <span class=\"h1\">",
"       Does being obese shorten a person&rsquo;s life?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Studies show that people who are obese die younger than people who are a healthy weight. They also show that the risk of death goes up the heavier a person is. The degree of increased risk depends on how long the person has been obese, and on what other medical problems he or she has.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119814\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you are overweight or obese, see your doctor or nurse. He or she might have suggestions on ways to lose weight.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119829\">",
"      <span class=\"h1\">",
"       Are there medical treatments that can help me lose weight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are medicines and surgery to help with weight loss. But those treatments are only for people with severe obesity who have not been able to lose weight through diet and exercise. Also, weight loss treatments do not take the place of diet and exercise. People who have those treatments must also change how they eat and how active they are.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119846\">",
"      <span class=\"h1\">",
"       What can I do to prevent the problems caused by being obese?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The obvious answer is that you can lose weight. But even if weight loss is not possible, you can improve your health and reduce your risk if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Become more active",
"        </strong>",
"        &ndash; Many types of physical activity can help, including walking. You can start with a few minutes a day and add more as you get stronger.",
"       </li>",
"       <li>",
"        <strong>",
"         Improve your diet",
"        </strong>",
"        &ndash; No single diet turns out to be better than any other. It is healthy to have regular meal times and smaller portions, and not to skip meals. Avoid sweets and processed snack foods, and instead eat more vegetables and fruits.",
"       </li>",
"       <li>",
"        <strong>",
"         Quit smoking",
"        </strong>",
"        (if you smoke)",
"       </li>",
"       <li>",
"        <strong>",
"         Limit alcohol",
"        </strong>",
"        &ndash; Drink no more than 1 drink a day if you are woman, and no more than 2 drinks a day if you are a man.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119861\">",
"      <span class=\"h1\">",
"       What increases a person&rsquo;s risk of being obese?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The thing that increases a person&rsquo;s risk the most is having an unhealthy lifestyle. Most people become obese because they simply eat too much and move too little. That&rsquo;s especially true of people who watch too much TV. But there are also a number of other factors that seem to increase the risk of obesity that many people do not know about. Here are some things that might affect a person&rsquo;s chance of becoming obese:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Mom&rsquo;s habits during pregnancy &ndash; Women who eat a lot of calories, have diabetes, or smoke during pregnancy have a higher chance of having babies who grow up to be obese.",
"       </li>",
"       <li>",
"        Formula feeding &ndash; Babies who are fed formula are more likely than babies who are breastfed to grow up to be obese.",
"       </li>",
"       <li>",
"        Habits and weight gain during childhood &ndash; People who are overweight or obese as children or as teens are more likely to be obese as adults.",
"       </li>",
"       <li>",
"        Sleeping too little &ndash; People who do not get enough sleep are more likely to become obese than people who sleep enough.",
"       </li>",
"       <li>",
"        Taking certain medicines &ndash; Long-term use of certain medicines, such as some medicines to treat depression, can cause a lot of weight gain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are also hormonal conditions that can increase the risk of becoming obese, but those conditions are to blame for only a tiny fraction of cases of obesity.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119884\">",
"      <span class=\"h1\">",
"       What if I want to have children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to have children, you should know that being obese can make it hard for a woman to get pregnant. It can also impair a man&rsquo;s ability to have sex, especially if the obese man has high blood pressure or diabetes. What&rsquo;s more, children born to obese parents have a high risk of being obese themselves.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119899\">",
"      <span class=\"h1\">",
"       What if my child is obese?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In children, obesity has many of the same risks as it does in adults. For example, it can increase the risk of diabetes, high blood pressure, asthma, and sleep apnea. It can also cause added problems related to childhood. For example, obesity can make children grow faster than normal and speed up sexual development in girls.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1674119914\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/31/14835?source=see_link\">",
"       Patient information: Weight loss surgery (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=see_link\">",
"       Patient information: Preventing type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/30/23010?source=see_link\">",
"       Patient information: My child is overweight (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       Patient information: Weight loss treatments (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"       Patient information: Weight loss surgery (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/53/3923?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83815 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3923=[""].join("\n");
var outline_f3_53_3923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119769\">",
"      What does it mean to be obese?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119784\">",
"      What are the health risks of being obese?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119799\">",
"      Does being obese shorten a person&rsquo;s life?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119814\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119829\">",
"      Are there medical treatments that can help me lose weight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119846\">",
"      What can I do to prevent the problems caused by being obese?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119861\">",
"      What increases a person&rsquo;s risk of being obese?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119884\">",
"      What if I want to have children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119899\">",
"      What if my child is obese?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1674119914\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/3/3125\">",
"      Your body mass index (BMI)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/30/23010?source=related_link\">",
"      Patient information: My child is overweight (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=related_link\">",
"      Patient information: Preventing type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=related_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/31/14835?source=related_link\">",
"      Patient information: Weight loss surgery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_53_3924="Mitochondrial genome";
var content_f3_53_3924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 654px\">",
"   <div class=\"ttl\">",
"    Mitochondrial genome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 634px; height: 804px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: MITOMAP: A human mitochondrial genome database. Available at: file://mitomap.org/pub/MITOMAP/MitomapFigures/mitomapgenome.pdf. (Accessed December 6, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3924=[""].join("\n");
var outline_f3_53_3924=null;
var title_f3_53_3925="Amantadine: Patient drug information";
var content_f3_53_3925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amantadine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     see \"Amantadine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"     see \"Amantadine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Amantadine;",
"     </li>",
"     <li>",
"      Mylan-Amantadine;",
"     </li>",
"     <li>",
"      PHL-Amantadine;",
"     </li>",
"     <li>",
"      PMS-Amantadine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2980901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amantadine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on soft food or liquid. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699155",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not freeze liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10759 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3925=[""].join("\n");
var outline_f3_53_3925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132677\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015708\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015707\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015712\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015713\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015715\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015710\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015711\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015716\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015717\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=related_link\">",
"      Amantadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=related_link\">",
"      Amantadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_53_3926="Irritable bowel syndrome";
var content_f3_53_3926=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Irritable bowel syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/53/3926/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3926/contributors\" id=\"au721\">",
"       Arnold Wald, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/53/3926/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3926/contributors\" id=\"se5165\">",
"       Nicholas J Talley, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/53/3926/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3926/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?3/53/3926?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      IRRITABLE BOWEL SYNDROME OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Irritable bowel syndrome (IBS) is a chronic condition of the digestive system. Its primary symptoms are abdominal pain and altered bowel habits (eg, constipation",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     diarrhea), but these symptoms have no identifiable cause.",
"    </p>",
"    <p>",
"     IBS is the most commonly diagnosed gastrointestinal condition and is second only to the common cold as a cause of absence from work. An estimated 10 to 20 percent of people in the general population experience symptoms of IBS, although only about 15 percent of affected people actually seek medical help.",
"    </p>",
"    <p>",
"     Several treatments and therapies are available for irritable bowel syndrome. These measures help alleviate symptoms, but do not cure the condition. The chronic nature of irritable bowel syndrome and the challenge of controlling its symptoms can be frustrating for both patients and healthcare providers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IRRITABLE BOWEL SYNDROME CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of theories about how and why irritable bowel syndrome (IBS) develops. Despite intensive research, the cause is not clear.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       One theory suggests that irritable bowel syndrome is caused by abnormal contractions of the colon and intestines (hence the term \"spastic bowel,\" which has sometimes been used to describe irritable bowel syndrome). Vigorous contractions of the intestines can cause severe cramps, providing the rationale for some of the treatments of IBS, such as antispasmodics and fiber (both of which help to regulate the contractions of the colon). However, abnormal contractions do not explain irritable bowel syndrome in all patients, and it is unclear whether the contractions are a symptom or cause of the disorder.",
"      </li>",
"      <li>",
"       Some people develop irritable bowel syndrome after a severe gastrointestinal infection (eg, Salmonella or Campylobacter, or viruses). It is not clear how the infection triggers IBS to develop, and most people with irritable bowel syndrome do not have a history of these infections.",
"      </li>",
"      <li>",
"       People with irritable bowel syndrome who seek medical help are more likely to suffer from anxiety and stress than those who do not seek help. Stress and anxiety are known to affect the intestine; thus, it is likely that anxiety and stress worsen symptoms. However, stress or anxiety is probably not the cause. Some studies have suggested that irritable bowel syndrome is more common in people who have a history of physical, verbal, or sexual abuse.",
"      </li>",
"      <li>",
"       Food intolerances are common in patients with irritable bowel syndrome, raising the possibility that it is caused by food sensitivity or allergy. This theory has been difficult to prove, although it continues to be studied. The best way to detect an association between symptoms of irritable bowel syndrome and food sensitivity is to eliminate certain food groups systematically (a process called an elimination diet), which should only be considered for patients in the care of a doctor or nutritionist. Eliminating foods without assistance can lead to omission of important sources of nutrition. In addition, unnecessary dietary restrictions can further worsen a person's quality of life.",
"       <br/>",
"       <br/>",
"       A number of foods are known to cause symptoms that mimic or aggravate irritable bowel syndrome, including dairy products (which contain lactose), legumes (such as beans), and cruciferous vegetables (such as broccoli, cauliflower, Brussels sprouts, and cabbage). These foods increase intestinal gas, which can cause cramps. Several medications also have effects on the intestines that may contribute to symptoms.",
"      </li>",
"      <li>",
"       Many researchers believe that irritable bowel syndrome is caused by heightened sensitivity of the intestines to normal sensations (so-called \"visceral hyperalgesia\"). This theory proposes that nerves in the bowels are overactive in people with irritable bowel syndrome, so that normal amounts of gas or movement are perceived as excessive and painful. Some patients with severe irritable bowel syndrome feel better when treated with medications that decrease pain perception in the intestine (such as low doses of imipramine or nortriptyline) (see",
"       <a class=\"local\" href=\"#H21\">",
"        'Antidepressants'",
"       </a>",
"       below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SYMPTOMS OF IRRITABLE BOWEL SYNDROME",
"     </span>",
"    </p>",
"    <p>",
"     Irritable bowel syndrome (IBS) often begins in young adulthood. Women are twice as likely as men to be diagnosed with irritable bowel syndrome in the United States and other western countries. In other countries, an equal number of men and women are diagnosed with irritable bowel syndrome. The most common symptom of irritable bowel syndrome is abdominal pain in association with changes in bowel habits (diarrhea",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     constipation).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Abdominal pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Abdominal pain is typically crampy and varies in intensity. Some people notice that emotional stress and eating worsen the pain, and that having a bowel movement relieves the pain. Some women with irritable bowel syndrome notice an association between pain episodes and their menstrual cycle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Changes in bowel habits",
"     </span>",
"     &nbsp;&mdash;&nbsp;Altered bowel habits are a second symptom of irritable bowel syndrome. This can include diarrhea, constipation, or alternating diarrhea and constipation. If diarrhea is the more common pattern, the condition is called diarrhea-predominant irritable bowel syndrome; if constipation is more common, the condition is called constipation-dominant irritable bowel syndrome.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Diarrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;A person with irritable bowel syndrome may have frequent loose stools. Bowel movements usually occur during the daytime, and most often in the morning or after meals. Diarrhea is often preceded by a sense of extreme urgency and followed by a feeling of incomplete emptying. About one-half of people with IBS also notice mucous discharge with diarrhea. Diarrhea occurring during sleep is very unusual with IBS. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"      \"Patient information: Chronic diarrhea in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Constipation",
"     </span>",
"     &nbsp;&mdash;&nbsp;The constipation of irritable bowel syndrome can be intermittent and last for days. Stools are often hard and pellet-shaped. You may not feel empty after a bowel movement, even when the rectum is empty. This faulty sensation can lead to straining and sitting on the toilet for prolonged periods of time. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      \"Patient information: Constipation in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Other symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other symptoms of irritable bowel syndrome include bloating, gas, and belching.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      IRRITABLE BOWEL SYNDROME DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Several intestinal disorders have symptoms that are similar to irritable bowel syndrome. Examples include malabsorption (abnormal absorption of nutrients), inflammatory bowel disease (such as ulcerative colitis and Crohn's disease), celiac disease, and microscopic colitis (uncommon diseases associated with intestinal inflammation).",
"    </p>",
"    <p>",
"     Because there is no single diagnostic test for irritable bowel syndrome, many clinicians compare your symptoms to formal sets of diagnostic criteria. However, these criteria are not accurate in distinguishing irritable bowel syndrome from other conditions in everyone. Thus, a medical history, physical examination, and select tests can help to rule out other medical conditions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most clinicians order routine blood tests in people with suspected irritable bowel syndrome; these tests are usually normal, but they can help rule out other medical conditions.",
"    </p>",
"    <p>",
"     Some clinicians also order more invasive tests, such as sigmoidoscopy or colonoscopy, especially in people over age 40 years. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      IRRITABLE BOWEL SYNDROME TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of different treatments and therapies for irritable bowel syndrome (IBS) [",
"     <a class=\"abstract\" href=\"UTD.htm?3/53/3926/abstract/1\">",
"      1",
"     </a>",
"     ]. Treatments are often given to reduce the pain and other symptoms of irritable bowel syndrome, and it may be necessary to try more than one combination of treatments to find the one that is most helpful for you. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"      \"Treatment of irritable bowel syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Treatment is usually a long-term process; during this process, it is important to communicate with your healthcare provider about symptoms, concerns, and any stressors or",
"     <span class=\"nowrap\">",
"      home/work/family",
"     </span>",
"     problems that develop.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Monitor symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first step in treating irritable bowel syndrome is usually to monitor symptoms, daily bowel habits, and any other factors that may affect your bowels. This can help to identify factors that worsen symptoms in some people with IBS, such as lactose or other food intolerances and stress. A daily diary can be helpful (",
"     <a class=\"graphic graphic_form graphicRef61226 \" href=\"UTD.htm?19/11/19646\">",
"      form 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Diet changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is reasonable to try eliminating foods that may aggravate irritable bowel syndrome, although this should be done with the assistance of a healthcare provider. Eliminating foods without assistance can potentially worsen symptoms or cause new problems if important food groups are omitted.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Lactose",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many clinicians recommend temporarily eliminating milk products since lactose intolerance is common and can aggravate irritable bowel syndrome or cause symptoms similar to IBS. The greatest concentration of lactose is found in milk and ice cream, although it is present in smaller quantities in yogurt, cottage and other cheeses, and any prepared foods that contain these ingredients (",
"     <a class=\"graphic graphic_table graphicRef55938 \" href=\"UTD.htm?32/38/33388\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     All lactose containing products should be eliminated for two weeks. If IBS symptoms improve, it is reasonable to continue avoiding lactose. If symptoms do not improve, you may resume eating lactose-containing foods.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Foods that cause gas",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many foods are only partially digested in the small intestines. When they reach the colon (large intestine), further digestion takes place, which may cause gas and cramps. Eliminating these foods temporarily is reasonable if gas or bloating is bothersome.",
"    </p>",
"    <p>",
"     The most common gas-producing foods are legumes (such as beans) and cruciferous vegetables (such as cabbage, Brussels sprouts, cauliflower, and broccoli). In addition, some people have trouble with onions, celery, carrots, raisins, bananas, apricots, prunes, sprouts, and wheat. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/14/6371?source=see_link\">",
"      \"Patient information: Gas and bloating (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Foods that are easier",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following table provides a list of foods that may be easier to digest in people with IBS (",
"     <a class=\"graphic graphic_table graphicRef69440 \" href=\"UTD.htm?38/1/38939\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Increasing dietary fiber",
"     </span>",
"     &nbsp;&mdash;&nbsp;Increasing dietary fiber (either by adding certain foods to the diet or using fiber supplements) may relieve symptoms of IBS, particularly if you have constipation (",
"     <a class=\"graphic graphic_table graphicRef52349 \" href=\"UTD.htm?28/61/29661\">",
"      table 3",
"     </a>",
"     ). By reading the product information panel on the side of the package, you can determine the number of grams of fiber per serving (",
"     <a class=\"graphic graphic_figure graphicRef51585 \" href=\"UTD.htm?38/31/39413\">",
"      figure 1",
"     </a>",
"     ). Fiber may also be helpful in some people with diarrhea predominant symptoms since it can improve the consistency of stools. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      \"Patient information: High-fiber diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A bulk-forming fiber supplement (such as psyllium or methylcellulose) may also be recommended to increase fiber intake since it is difficult to consume enough fiber in the diet. Fiber supplements should be started at a low dose and increased slowly over several weeks to reduce the symptoms of excessive intestinal gas, which can occur in some people when beginning fiber therapy.",
"    </p>",
"    <p>",
"     Fiber can make some people with irritable bowel syndrome more bloated and uncomfortable. If this happens, it is best to decrease fiber intake and consider other laxative treatments for constipation. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      \"Patient information: Constipation in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Psychosocial therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stress and anxiety can worsen irritable bowel syndrome in some people. The best approach for reducing stress and anxiety depends upon your situation and the severity of your symptoms. Have an open discussion with your clinician about the possible role that stress and anxiety could be having on your symptoms, and together decide upon the best course of action.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Some people benefit from formal counseling, with or without antidepressant or antianxiety medications [",
"       <a class=\"abstract\" href=\"UTD.htm?3/53/3926/abstract/2\">",
"        2",
"       </a>",
"       ]. Other treatments, such as hypnosis and cognitive behavioral therapy may also be helpful. Hypnosis is a state of altered consciousness that allows you to focus away from your anxiety or stress. Patients who are hypnotized are not sleeping, but are actually in a state of heightened imagination, similar to daydreaming. An expert can hypnotize an individual or you can learn self-hypnosis techniques.",
"       <br/>",
"       <br/>",
"       Cognitive behavioral therapy helps you to focus on a particular problem in a limited time period. You learn how your thoughts contribute to anxiety or stress and learn how to change these thoughts.",
"      </li>",
"      <li>",
"       Participation in a support group can also be valuable.",
"      </li>",
"      <li>",
"       Many patients find that daily exercise is helpful in maintaining a sense of well-being. Exercise can also have favorable effects on the bowels. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"        \"Patient information: Exercise (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Irritable bowel syndrome medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although many drugs are available to treat the symptoms of irritable bowel syndrome, these drugs do not cure the condition. They are primarily used to relieve symptoms. The choice among these medications depends in part upon whether you have diarrhea, constipation, or pain- predominant irritable bowel syndrome.",
"    </p>",
"    <p>",
"     As a general rule, medications are reserved for people whose symptoms have not adequately responded to more conservative measures such as changes in diet and fiber supplements.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Anticholinergic medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticholinergic drugs block the nervous system's stimulation of the gastrointestinal tract, helping to reduce severe cramping and irregular contractions of the colon.",
"    </p>",
"    <p>",
"     Drugs in this category include dicyclomine (Bentyl&reg;) and hyoscyamine (Levsin&reg;). These drugs may be particularly helpful when taken preventively (ie, before symptoms) and thus are most helpful if you can predict the onset of your symptoms. Common side-effects include dry mouth and eyes and blurred vision.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Antidepressants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many tricyclic antidepressants (TCAs) have a pain relieving effect in people with irritable bowel syndrome. The dose of TCAs is typically much lower than that used for treating depression. It is believed that these drugs reduce pain perception when used in low doses, although the exact mechanism of their benefit is unknown.",
"    </p>",
"    <p>",
"     TCAs commonly used for pain management include amitriptyline, imipramine, desipramine, and nortriptyline. It is common to experience fatigue when starting a TCA; this is not always an undesirable side effect since it can help improve sleep when TCAs are taken in the evening. TCAs are generally started in low doses and increased gradually. Their full effect may not be seen for three to four weeks.",
"    </p>",
"    <p>",
"     TCAs also slow movement of contents through the gastrointestinal tract and may be most helpful in people with diarrhea-predominant irritable bowel syndrome.",
"    </p>",
"    <p>",
"     Another class of antidepressants, the selective serotonin reuptake inhibitors, may be recommended if you have both irritable bowel syndrome and depression. Common SSRIs include fluoxetine (Prozac&reg;), sertraline (Zoloft&reg;), paroxetine (Paxil&reg;), citalopram (Celexa&reg;), and escitalopram (Lexapro&reg;) Other antidepressant medications that may be recommended include mirtazapine (Remeron&reg;), venlafaxine (Effexor&reg;), and duloxetine (Cymbalta&reg;). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Antidiarrheal drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;The drugs loperamide (Imodium&reg;) or diphenoxylate with atropine (Lomotil&reg;) can help slow the movement of stool through the digestive tract. Loperamide and",
"     <span class=\"nowrap\">",
"      diphenoxylate/atropine",
"     </span>",
"     are most helpful if you have diarrhea-predominant irritable bowel syndrome. However, clinicians usually recommend that these drugs should only be used as needed rather than on a continuous basis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Anti-anxiety drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anti-anxiety drugs reduce anxiety. Diazepam (Valium&reg;), lorazepam (Ativan&reg;), and clonazepam (Klonopin&reg;) belong to this class of drugs. Anti-anxiety drugs are occasionally prescribed for people with short-term anxiety that is worsening their irritable bowel syndrome symptoms. However, these drugs should only be taken for short periods of time since they can be addictive.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Alosetron",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alosetron (Lotronex&reg;) blocks a hormone that is involved in intestinal contractions and sensations. It is approved to treat women with irritable bowel syndrome whose predominant symptom is diarrhea. However, it was withdrawn from the market soon after its introduction because of concerns related to safety. It was reintroduced and is currently available, although certain prescribing guidelines must be followed. Further information is available on the manufacturer's web site (www.lotronex.com).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Lubiprostone",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lubiprostone (Amitiza&reg;) is available for treatment of severe constipation and irritable bowel syndrome in women over 18 years who have not responded to other treatments. It works by increasing intestinal fluid secretion. It is expensive compared to other agents. Further testing is needed to clarify the effectiveness and long-term safety of lubiprostone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h3\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The role of antibiotics in the treatment of irritable bowel syndrome remains unclear. There appear to be some patients whose irritable bowel syndrome symptoms benefit from antibiotic treatment. However, more research is needed before antibiotics are recommended for treatment of irritable bowel syndrome.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      HERBS AND NATURAL THERAPIES FOR IRRITABLE BOWEL SYNDROME",
"     </span>",
"    </p>",
"    <p>",
"     A number of herbal and natural therapies have been advertised (especially on the internet) for the treatment of irritable bowel syndrome. Unfortunately, there is no evidence supporting their benefit. Although small studies may support some of these therapies, the studies are either too small or have major flaws that make definitive conclusions impossible.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Peppermint oil &ndash; There is some evidence supporting the use of peppermint oil, although it is difficult to make definitive conclusions. Peppermint oil can cause or worsen heartburn.",
"      </li>",
"      <li>",
"       Acidophilus &ndash; There is increasing interest in the possible beneficial effects of \"healthy\" bacteria (probiotics) in a variety of intestinal diseases including IBS. Whether supplements containing these bacteria are of any benefit is unproven. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"        \"Probiotics for gastrointestinal diseases\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Unproven &ndash; Chamomile tea is of unproven benefit in irritable bowel syndrome. Furthermore, chamomile can aggravate allergies in people who tend to be allergic to grasses. Evening primrose oil, a supplement containing gamma linolenic acid, is of unproven benefit. Fennel seeds are of unproven benefit.",
"      </li>",
"      <li>",
"       Potentially unsafe &ndash; Wormwood is of unproven benefit and may be unsafe. Wormwood oil can cause damage to the nervous system. Comfrey is of unproven benefit and can cause serious liver problems.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H29\">",
"     <span class=\"h1\">",
"      IRRITABLE BOWEL SYNDROME PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Although irritable bowel syndrome can produce substantial physical discomfort and emotional distress, most people with irritable bowel syndrome do not develop serious long-term health conditions. Furthermore, the vast majority of people with irritable bowel syndrome learn to control their symptoms.",
"    </p>",
"    <p>",
"     It is important to work with a clinician to monitor symptoms over time. If symptoms change over time, further testing may be recommended. Over time, less than 5 percent of people diagnosed with irritable bowel syndrome will be diagnosed with another gastrointestinal condition.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H30\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Irritable bowel syndrome (IBS) is a common gastrointestinal disorder affecting approximately 10 to 20 percent of the population. Although the condition cannot be cured, treatments are available to alleviate symptoms.",
"      </li>",
"      <li>",
"       No single cause of irritable bowel syndrome has been identified, although there are theories that gastrointestinal abnormalities, food intolerance, and psychological issues may be involved. (See",
"       <a class=\"local\" href=\"#H2\">",
"        'Irritable bowel syndrome causes'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       The primary symptoms of irritable bowel syndrome are abdominal pain and changes in bowel habits (eg, diarrhea",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       constipation). Abdominal pain can vary in location and severity. Patients can experience primarily diarrhea, primarily constipation, or an alternating pattern of the two; additional gastrointestinal symptoms may also occur. (See",
"       <a class=\"local\" href=\"#H3\">",
"        'Symptoms of irritable bowel syndrome'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       There is no single diagnostic test for irritable bowel syndrome, and several other gastrointestinal conditions produce similar symptoms; a patient's history, physical examination, and blood test results are all reviewed to rule out other disorders and establish a diagnosis of IBS. (See",
"       <a class=\"local\" href=\"#H9\">",
"        'Irritable bowel syndrome diagnosis'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       There are many different treatments available to relieve the symptoms of irritable bowel syndrome; these include the monitoring of symptoms and patterns, adjustment of the diet to increase fiber and eliminate foods that can worsen symptoms, psychosocial therapy (since stress may aggravate IBS), and medication. Treatments are often used in combination, and because of the variability of symptoms, different treatments work for different people. (See",
"       <a class=\"local\" href=\"#H11\">",
"        'Irritable bowel syndrome treatment'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Many herbal and natural therapies have been advertised for the treatment of irritable bowel syndrome; however, these therapies have not been proven effective and they are not recommended. (See",
"       <a class=\"local\" href=\"#H28\">",
"        'Herbs and natural therapies for irritable bowel syndrome'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Although irritable bowel syndrome can cause pain and stress, the majority of patients are able to control their symptoms and live a normal life without developing serious health problems. (See",
"       <a class=\"local\" href=\"#H29\">",
"        'Irritable bowel syndrome prognosis'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H311\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2876848\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31265?source=see_link\">",
"      Patient information: Irritable bowel syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/26/11684?source=see_link\">",
"      Patient information: Lactose intolerance (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/18/20770?source=see_link\">",
"      Patient information: Hirschsprung disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2876856\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/14/6371?source=see_link\">",
"      Patient information: Gas and bloating (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"      Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/48/31490?source=see_link\">",
"      Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H33\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38727?source=see_link\">",
"      Alosetron hydrochloride (Lotronex) for irritable bowel syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24872?source=see_link\">",
"      Intestinal gas and bloating",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"      Lactose intolerance",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/\">",
"      www.gastro.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Gastroenterology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acg.gi.org/\">",
"      www.acg.gi.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Foundation for Functional Gastrointestinal Disorders (IFFGD)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.iffgd.org/\">",
"      www.iffgd.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H34\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Irritable Bowel Syndrome Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://ibs.about.com/forum\">",
"      file://ibs.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?3/53/3926/abstract/3-10\">",
"      3-10",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?3/53/3926?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/1\">",
"      American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/2\">",
"      Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/3\">",
"      Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/4\">",
"      Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/5\">",
"      Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/6\">",
"      Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/7\">",
"      Drossman DA. Functional abdominal pain syndrome. Clin Gastroenterol Hepatol 2004; 2:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/8\">",
"      Liu JP, Yang M, Liu YX, et al. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; :CD004116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/9\">",
"      Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3926/abstract/10\">",
"      Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol Clin North Am 2005; 34:281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f3_53_3926=[""].join("\n");
var outline_f3_53_3926=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           IRRITABLE BOWEL SYNDROME OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IRRITABLE BOWEL SYNDROME CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SYMPTOMS OF IRRITABLE BOWEL SYNDROME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           IRRITABLE BOWEL SYNDROME DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           IRRITABLE BOWEL SYNDROME TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           HERBS AND NATURAL THERAPIES FOR IRRITABLE BOWEL SYNDROME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H29\">",
"           IRRITABLE BOWEL SYNDROME PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H30\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/31/39413\" title=\"figure 1\">",
"           Nutrition label fiber PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          FORMS",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?19/11/19646\" title=\"form 1\">",
"           Stool and diet history PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?32/38/33388\" title=\"table 1\">",
"           Lactose content of different foods PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?38/1/38939\" title=\"table 2\">",
"           Foods better tolerated PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29661\" title=\"table 3\">",
"           Fiber in foods PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f3_53_3927="Iron overload liver Perls";
var content_f3_53_3927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Liver biopsy in hereditary hemochromatosis (iron stain)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perls' Prussian blue stain of a liver biopsy from a patient with hereditary hemochromatosis. Left panel: Low power view shows intense iron staining of hepatocytes. The blue-stained iron deposits typically start at the periphery of the liver lobule and extend centrally. Right panel: High power view shows intense iron staining (in blue) of hepatocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3927=[""].join("\n");
var outline_f3_53_3927=null;
var title_f3_53_3928="Renal disease associated with hepatitis C virus after renal transplantation";
var content_f3_53_3928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal disease associated with hepatitis C virus after renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3928/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3928/contributors\">",
"     Svetlozar Natov, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3928/contributors\">",
"     Brian JG Pereira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3928/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3928/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3928/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3928/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/53/3928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) has been implicated in the pathogenesis of renal disease in native as well as transplanted kidneys. In native kidneys, HCV has been associated with membranoproliferative glomerulonephritis (MPGN), with or without mixed cryoglobulinemia, and membranous nephropathy (MN). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among renal transplant recipients with HCV infection, both recurrent glomerular disease (among those in whom glomerular disease was the cause of end-stage renal disease) and de novo MPGN and MN can occur.",
"   </p>",
"   <p>",
"    HCV infection may be more commonly associated with glomerular disease in renal transplants than in native kidneys. One possible mechanism is that immunosuppressive therapy to prevent rejection increases the titer of HCV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/1\">",
"     1",
"    </a>",
"    ]. The higher number of HCV particles may lead to an alteration in the ratio of antibody to antigen in immune complexes, resulting in decreased clearance and increased deposition of viral complexes in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCV-infected renal transplant recipients have worse patient and allograft survival after transplantation when compared with non infected renal transplant recipients. The increased mortality in the posttransplant period in this population has been associated not only with the progression of liver disease but also with extrahepatic complications of HCV infection, including renal disease. Consequently, early detection, prevention, and treatment of HCV-related renal disease after kidney transplantation could improve posttransplant outcomes in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to HCV-associated renal disease in the renal transplant recipient will be reviewed here. The overall effect of HCV infection in renal transplantation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HCV-ASSOCIATED RENAL DISEASE POSTTRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the incidence, type, and manifestations of renal disease among renal transplant recipients with HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/4-12\">",
"     4-12",
"    </a>",
"    ]. The most common manifestations are proteinuria, MPGN, and membranous nephropathy.",
"   </p>",
"   <p>",
"    Renal manifestations of HCV infection are not limited to renal transplant recipients. Both de novo MPGN and de novo mixed cryoglobulinemia have been observed in HCV-infected patients after liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Posttransplant proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria has been used as a marker of disease in the renal allograft among anti-HCV positive transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/4,15-18\">",
"     4,15-18",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of almost 1000 renal transplant recipients, proteinuria of more than 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      was detected in 23 percent of the 140 anti-HCV positive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the prevalence of proteinuria among the other 856 anti-HCV negative patients was not reported and the association of HCV with proteinuria and renal disease was not confirmed.",
"     </li>",
"     <li>",
"      In a group of 868 renal transplant recipients, the seropositive rate for HCV was 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/19\">",
"       19",
"      </a>",
"      ]. Persistent proteinuria was more prevalent among HCV positive compared with HCV negative patients. There was no significant difference in mortality and graft survival rate between HCV positive and negative patients, although renal function differed between the two groups at different points of the clinical course [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 322 consecutive renal transplant recipients, the presence of anti-HCV at the time of transplantation was strongly associated with proteinuria (relative risk = 5.36) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/16\">",
"       16",
"      </a>",
"      ]. Recipients with persistent proteinuria (defined as proteinuria &gt;1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      over three months from onset) had significantly worse graft survival rates compared to nonproteinuric recipients at one year (90.7 versus 95.6 percent) and five years (41 versus 92 percent, respectively). Despite the strong association between anti-HCV and proteinuria, patient and graft survival rates among anti-HCV-positive and anti-HCV-negative recipients were similar.",
"      <br/>",
"      <br/>",
"      Histopathology from renal transplant biopsies performed in 26 of the 44 proteinuric patients revealed that de novo glomerular lesions were more frequent among anti-HCV positive recipients (three out of seven patients, 43 percent) compared to anti-HCV negative recipients (4 out of 19 patients, 21 percent); this difference was not statistically significant, perhaps because of the small number of patients. The glomerular lesions were mostly consistent with transplant glomerulopathy and none of the proteinuric anti-HCV-positive recipients had MPGN.",
"     </li>",
"     <li>",
"      Among 96 renal transplant recipients who underwent diagnostic allograft biopsy for proteinuria &gt;1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      persistent microhematuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased serum creatinine concentration five to six years after transplantation, proteinuria was significantly higher and serum albumin was markedly lower in HCV-positive compared to HCV-negative patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/17\">",
"       17",
"      </a>",
"      ]. The HCV-positive patients were more likely to have nephrotic syndrome (36 versus 12 percent), persistent microhematuria (73 versus 35 percent), and MPGN (45 versus 6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations indicate that proteinuria in HCV-infected renal transplant recipients may or may not indicate HCV-associated disease in the renal allograft.",
"   </p>",
"   <p>",
"    However, since proteinuria is a common manifestation of kidney disease in HCV-infected kidney transplant recipients, KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease recommend that HCV-infected kidney transplant recipients have baseline protein-to-creatinine ratios and urinalyses within the first two weeks after transplantation, or as soon as a stable level of kidney function is established. Subsequently, patients should be tested for proteinuria at least every three to six months. These guidelines also suggest that patients who develop new onset proteinuria (either urine",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio &gt;1 or 24-hour urine protein greater than 1 g on two or more occasions) or microscopic hematuria without other identifiable cause should undergo an allograft biopsy studied with light microscopy, immunofluorescence techniques and electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/3\">",
"     3",
"    </a>",
"    ]. Histological findings characteristic of cryoglobulinemic MPGN may require consideration for specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Membranoproliferative glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in native kidneys, MPGN with or without mixed cryoglobulinemia has been described in association with HCV in the renal allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/4-6,17,20\">",
"     4-6,17,20",
"    </a>",
"    ]. The following observations have been noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MPGN is a frequent finding in patients with proteinuria and hematuria.",
"     </li>",
"     <li>",
"      It can occur as recurrent or de novo disease; in addition, chronic transplant glomerulopathy can have a membranoproliferative pattern on histologic examination.",
"     </li>",
"     <li>",
"      The presence of HCV-associated MPGN is associated with a worse long-term renal outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations are derived in part from some of the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series cited above, de novo MPGN was present in 20 of 44 patients (45 percent) who underwent diagnostic allograft biopsy because of proteinuria &gt;1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      persistent microhematuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increase increased serum creatinine concentration five to six years after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/17\">",
"       17",
"      </a>",
"      ]. The prognosis of de novo MPGN in HCV-positive patients was significantly worse than in those who were HCV-negative.",
"     </li>",
"     <li>",
"      Another report evaluated 98 renal transplant recipients with HCV infection; renal biopsies were performed on eight patients with proteinuria greater than 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/4\">",
"       4",
"      </a>",
"      ]. Five had MPGN and the other three had chronic rejection. None of the five patients with MPGN had this disorder as his or her original renal disease. The onset of proteinuria was variable: it occurred within three months after transplantation in two, and in 5 to 10 years in the other three.",
"     </li>",
"     <li>",
"      In a cohort of 399 renal transplant recipients with a 29 percent prevalence of HCV infection, MPGN type 1 was reported in 15 patients, 8 of whom were anti-HCV positive. There was a statistically significant association between HCV infection and the occurrence of MPGN type I in the renal allograft with the development of progressive renal failure and eventual return to dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Membranous nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy (MN) in renal transplant recipients has been associated with HCV infection. However, it is unclear if there is an etiologic relationship.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series cited above of patients who underwent diagnostic allograft biopsy because of proteinuria &gt;1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      persistent microhematuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increase increased serum creatinine concentration five to six years after transplantation, de novo MN was present in 8 of 44 biopsies from anti-HCV positive patients and in 4 of 52 from anti-HCV negative patients (18.2 versus 7.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 2045 patients transplanted at a single center between 1980 and 1994, 409 (20 percent) were anti-HCV-positive [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/21\">",
"       21",
"      </a>",
"      ]. Fifteen of the HCV-positive patients (3.7 percent) developed biopsy-proven MN in the renal allograft 24 months after transplantation. HCV infection was preferentially associated with MN rather than MPGN. The clinical presentation and outcomes of HCV-associated MN (persistent heavy proteinuria and progressive deterioration of renal function) were similar to posttransplant idiopathic de novo MN. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34088?source=see_link\">",
"       \"Membranous nephropathy and renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these observations, another report of 399 renal transplant recipients failed to demonstrate any association between HCV infection and the occurrence of MN [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/20\">",
"     20",
"    </a>",
"    ]. Among the 16 cases of MN, only 5 (31 percent) were anti-HCV positive, which was similar to the 29 percent prevalence of HCV infection in the entire cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal thrombotic microangiopathy (RTMA) may be observed in HCV-infected renal transplant recipients, particularly among those with anticardiolipin antibodies. This association was suggested in a report of 18 anti-HCV positive patients, five of whom developed RTMA between 5 and 120 days after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/7\">",
"     7",
"    </a>",
"    ]. Anticardiolipin antibodies were found in all five patients of these patients, but in only one of the 13 without a microangiopathy. The hypothesis that anticardiolipin antibodies, HCV infection, and renal thrombosis were correlated was also supported by the observation that normal anticardiolipin antibody titers were found in the seven HCV-negative transplant recipients who presented with",
"    <span class=\"nowrap\">",
"     RTMA/hemolytic",
"    </span>",
"    uremic syndrome during the same time period and served as a control group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute transplant glomerulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute transplant glomerulopathy, which may be an atypical variant of acute cellular rejection, has a high prevalence among HCV-positive renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic transplant glomerulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic transplant glomerulopathy, which is usually believed to be a glomerular manifestation of chronic rejection, has been reported in association with HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Affected patients present with proteinuria and deterioration of allograft function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HCV-associated glomerular disease is usually established by renal biopsy. Among patients in whom MPGN was not the primary disease in the native kidneys, the major differential is with the MPGN pattern of the transplant glomerulopathy induced by chronic allograft rejection.",
"   </p>",
"   <p>",
"    Both disorders present with mesangial cell proliferation and glomerular basement membrane splitting and are often indistinguishable on light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef58239 \" href=\"UTD.htm?5/17/5401\">",
"     picture 1",
"    </a>",
"    ). However, electron microscopy typically shows large electron-dense immune complex deposition in the glomerular basement membrane in MPGN (",
"    <a class=\"graphic graphic_picture graphicRef64411 \" href=\"UTD.htm?8/37/8793\">",
"     picture 2",
"    </a>",
"    ) and only subendothelial accumulation of electron-lucent material in transplant glomerulopathy (",
"    <a class=\"graphic graphic_picture graphicRef79914 \" href=\"UTD.htm?27/6/27753\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with MPGN, there is no way to determine on renal biopsy whether HCV infection is responsible for the glomerular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT WITH INTERFERON ALFA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa (IFNa) is effective in some patients with cryoglobulinemia and MPGN associated with HCV infection who have not undergone renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, there are extremely limited data evaluating the efficacy and complications of IFNa therapy in the treatment of possible HCV-related cryoglobulinemia or de novo or recurrent glomerular disease in renal transplant recipients. One report found variable effects of IFNa in two patients with HCV infection who had features of both MPGN and transplant glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first patient, the serum creatinine concentration improved from 3.5 to 2.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (309 to 185",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      after two months of therapy. Values for urinary protein excretion were not available. The patient subsequently discontinued IFNa after four months of therapy because of side effects. One month later, the serum creatinine concentration had increased to 2.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (247",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"     </li>",
"     <li>",
"      In the second patient, HCV RNA was undetectable after one month of therapy with IFNa. After three months, however, IFNa was discontinued because the serum creatinine concentration had risen from 2.0 to 4.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177 to 398",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Ten days after cessation of therapy, HCV RNA was again detected in the serum. A repeat renal biopsy revealed focal segmental glomerulosclerosis and increased tubular atrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Increased incidence of rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major stumbling block to the use of IFNa in renal transplant recipients has been the onset of acute rejection with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition to antiviral activity, IFNa has pleiotropic effects including antiproliferative and immunomodulatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/23\">",
"     23",
"    </a>",
"    ]. IFNa also induces cytokine gene expression, increased cell surface expression of HLA antigens, and enhanced function of natural killer cells, cytotoxic T cells, and monocytes.",
"   </p>",
"   <p>",
"    These immunostimulant effects can result in enhanced allograft rejection when IFNa is used in the transplant patient with CMV or hepatitis C. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of IFNa as prophylaxis against CMV disease in renal transplant recipients has been associated with a high incidence of steroid-resistant allograft rejection resulting in graft loss [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. In a report of 50 such patients, immunoprophylaxis with IFNa was associated with six cases of rejection resulting in allograft loss compared to no allograft loss in those in whom immunoprophylaxis was not administered [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most studies have noted an increased risk of acute rejection (40 to 100 percent) among renal transplant recipients treated with IFNa for chronic liver disease due to HCV [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]. Even stable patients are at risk as irreversible rejection and return to dialysis occurred in patients treated with IFNa as late as eight years after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high risk of renal transplant rejection and not well documented benefits of IFNa therapy in renal transplant recipients with HCV-associated glomerulopathy, KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease recommend that treatment with IFN-based therapy generally be avoided in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/3\">",
"     3",
"    </a>",
"    ]. Any decision to use IFNa should be individualized and the potential benefit weighed against the risks of rejection and return to dialysis.",
"   </p>",
"   <p>",
"    At present, we do",
"    <strong>",
"     not",
"    </strong>",
"    use IFNa in transplant recipients with HCV-associated renal disease.",
"   </p>",
"   <p>",
"    By comparison,",
"    <strong>",
"     pretransplant",
"    </strong>",
"    IFNa treatment of HCV infection in dialysis patients waiting for a kidney transplant may modify the incidence of HCV-associated kidney allograft disease in the posttransplant period. This also seems to be a safer strategy since it would eliminate the need of IFNa treatment of HCV infection after transplantation and thus would prevent the risk of IFNa-induced acute allograft rejection. Issues surrounding this strategy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31114?source=see_link\">",
"     \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT WITH RIBAVIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , either alone or in combination therapy with IFNa, has been evaluated in",
"    <strong>",
"     liver transplant recipients",
"    </strong>",
"    with recurrent HCV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=see_link\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one report, four HCV-infected liver transplant recipients developed nephrotic syndrome due to HCV-related glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/30\">",
"     30",
"    </a>",
"    ]. Renal biopsy revealed MPGN in three patients and MN in one. Continuous therapy with low dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    resulted in a marked decrease in proteinuria with attenuation or resolution of the nephrotic syndrome in all patients. No graft rejections occurred. Surprisingly, despite the apparent favorable clinical effect, viremia was not significantly changed by ribavirin therapy. These findings suggest that ribavirin may act upon HCV-related glomerular lesions through a mechanism other than a reduction in viral load.",
"   </p>",
"   <p>",
"    At present, little information is available on the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    therapy on HCV-related glomerulopathy in the renal allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/31\">",
"     31",
"    </a>",
"    ]. However, it is important to realize that the clearance of ribavirin is impaired in patients with renal dysfunction, and that ribavirin is",
"    <strong>",
"     not recommended",
"    </strong>",
"    for patients with a creatinine clearance below 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link&amp;anchor=H12#H12\">",
"     \"Renal disease associated with hepatitis C virus infection\", section on 'Interferon alfa plus ribavirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8756227\">",
"    <span class=\"h1\">",
"     USE OF PROTEASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatitis C virus protease inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    , are used for the treatment of chronic genotype 1 HCV infection in the non-transplant population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    has been adequately studied in organ transplant recipients. Telaprevir has been shown to significantly increase the concentrations of both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/32\">",
"     32",
"    </a>",
"    ]. We recommend NOT using telaprevir among renal transplant recipients until studies demonstrating its safety have been done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT WITH ANTIPROTEINURIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of nonspecific antiproteinuric measures, such as blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), could be beneficial in HCV-infected renal transplant recipients. While we are not aware of any studies in this population in particular, the benefit of the treatment with",
"    <span class=\"nowrap\">",
"     ACEI/ARB",
"    </span>",
"    has generally been shown in kidney transplant recipients. In these studies, treatment with",
"    <span class=\"nowrap\">",
"     ACEI/ARB",
"    </span>",
"    has been found to reduce proteinuria and slow down the progression of chronic kidney allograft disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Consequently, KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease recommend antiproteinuric therapy with",
"    <span class=\"nowrap\">",
"     ACEI/ARB",
"    </span>",
"    to be used in HCV-infected renal transplant recipients as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10382233\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis C virus (HCV) has been implicated in the pathogenesis of two renal diseases in native and transplanted kidneys. These include membranoproliferative glomerulonephritis (MPGN), with or without mixed cryoglobulinemia, and membranous nephropathy (MN). Among renal transplant recipients with HCV infection, both recurrent and de novo MPGN and MN can occur. In addition, a renal thrombotic microangiopathy (RTMA) may be observed in HCV-infected renal transplant recipients, particularly among those with anticardiolipin antibodies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Membranoproliferative glomerulonephritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Membranous nephropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Renal thrombotic microangiopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proteinuria is a common manifestation of kidney disease in HCV-infected kidney transplant recipients. HCV-infected kidney transplant recipients should have baseline protein-to-creatinine ratios and urinalyses within the first two weeks after transplantation, or as soon as a stable level of kidney function is established. Subsequently, patients should be tested for proteinuria at least every three to six months. Patients who develop new onset proteinuria (either urine",
"      <span class=\"nowrap\">",
"       protein/creatinine",
"      </span>",
"      ratio &gt;1 or 24-hour urine protein greater than 1 g on two or more occasions) or microscopic hematuria without other identifiable cause should undergo an allograft biopsy studied with light microscopy, immunofluorescence techniques and electron microscopy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Posttransplant proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HCV-associated glomerular disease is usually established by renal biopsy. Among patients in whom MPGN was not the primary disease in the native kidneys, the major differential diagnosis is transplant glomerulopathy induced by chronic allograft rejection. Among patients with MPGN, there is no way to determine on renal biopsy whether HCV infection is responsible for the glomerular disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are limited data evaluating the efficacy and complications of Interferon alfa (IFNa) therapy in the treatment of HCV-related cryoglobulinemia or glomerular disease in renal transplant recipients. A major stumbling block to the use of IFNa in renal transplant recipients has been the onset of acute rejection with treatment related to immunostimulant effects. KDIGO clinical practice guidelines recommend that treatment with IFN-based therapy generally be avoided in this population. Any decision to use IFNa should be individualized and the potential benefit weighed against the risks of rejection. We do",
"      <strong>",
"       not",
"      </strong>",
"      use IFNa in transplant recipients with HCV-associated renal disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment with interferon alfa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pretransplant IFNa treatment of HCV infection in dialysis patients waiting for a kidney transplant may modify the incidence of HCV-associated kidney allograft disease in the posttransplant period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31114?source=see_link\">",
"       \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are limited data on the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      therapy on HCV-related glomerulopathy in the renal allograft. We recommend not using ribavirin for patients with a creatinine clearance below 50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment with ribavirin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link&amp;anchor=H12#H12\">",
"       \"Renal disease associated with hepatitis C virus infection\", section on 'Interferon alfa plus ribavirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonspecific antiproteinuric measures, such as blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), may be beneficial in HCV-infected renal transplant recipients. KDIGO clinical practice guidelines recommend antiproteinuric therapy with",
"      <span class=\"nowrap\">",
"       ACEI/ARB",
"      </span>",
"      to be used in HCV-infected renal transplant recipients as tolerated. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment with antiproteinuric agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/1\">",
"      Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/2\">",
"      Burstein DM, Rodby RA. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. J Am Soc Nephrol 1993; 4:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/3\">",
"      Kidney disease: improving global outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; (suppl 109):s1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/4\">",
"      Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/5\">",
"      Cruzado JM, Gil-Vernet S, Ercilla G, et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996; 7:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/6\">",
"      Gallay BJ, Alpers CE, Davis CL, et al. Glomerulonephritis in renal allografts associated with hepatitis C infection: a possible relationship with transplant glomerulopathy in two cases. Am J Kidney Dis 1995; 26:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/7\">",
"      Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/8\">",
"      Cosio FG, Roche Z, Agarwal A, et al. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996; 28:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/9\">",
"      Cosio FG, Sedmak DD, Henry ML, et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/10\">",
"      Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/11\">",
"      Baid S, Cosimi AB, Tolkoff-Rubin N, et al. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/12\">",
"      Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol 2007; 2:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/13\">",
"      Rahamimov R, Ilan Y, Eid A, et al. Hepatitis C-associated cryoglobulinemia after liver transplantation. Transplantation 1995; 60:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/14\">",
"      Cantarell MC, Charco R, Capdevila L, et al. Outcome of hepatitis C virus-associated membranoproliferative glomerulonephritis after liver transplantation. Transplantation 1999; 68:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/15\">",
"      Brunkhorst R, Kliem V, Koch KM. Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C. Nephron 1996; 72:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/16\">",
"      Hestin D, Guillemin F, Castin N, et al. Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation 1998; 65:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/17\">",
"      Cruzado JM, Carrera M, Torras J, Griny&oacute; JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/18\">",
"      Mahmoud IM, Elhabashi AF, Elsawy E, et al. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis 2004; 43:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/19\">",
"      Romero E, Galindo P, Bravo JA, et al. Hepatitis C virus infection after renal transplantation. Transplant Proc 2008; 40:2933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/20\">",
"      Hammoud H, Haem J, Laurent B, et al. Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant 1996; 11 Suppl 4:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/21\">",
"      Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/22\">",
"      Fehr T, Amb&uuml;hl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/23\">",
"      Black M, Peters M. Alpha-interferon treatment of chronic hepatitis C: need for accurate diagnosis in selecting patients. Ann Intern Med 1992; 116:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/24\">",
"      Kramer, P, Ten Kate, FJ, Bijnen, AB, et al. The pathology of interferon induced renal allograft lesions. Transplant Proc 1985; 17:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/25\">",
"      Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/26\">",
"      Ozg&uuml;r O, Boyacio��lu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/27\">",
"      Harihara Y, Kurooka Y, Yanagisawa T, et al. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 1994; 26:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/28\">",
"      Rostaing L, Izopet J, Baron E, et al. Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol Dial Transplant 1995; 10 Suppl 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/29\">",
"      Chan TM, Lok AS, Cheng IK, Ng IO. Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon. Transplantation 1993; 56:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/30\">",
"      Pham HP, F&eacute;ray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/31\">",
"      Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/32\">",
"      Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/33\">",
"      Zaltzman JS, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004; 19:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/34\">",
"      Montanaro D, Gropuzzo M, Tulissi P, et al. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. Transplant Proc 2005; 37:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3928/abstract/35\">",
"      Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7310 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3928=[""].join("\n");
var outline_f3_53_3928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10382233\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HCV-ASSOCIATED RENAL DISEASE POSTTRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Posttransplant proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute transplant glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic transplant glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT WITH INTERFERON ALFA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Increased incidence of rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT WITH RIBAVIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8756227\">",
"      USE OF PROTEASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT WITH ANTIPROTEINURIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10382233\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7310|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/17/5401\" title=\"picture 1\">",
"      Transplant glomerulopathy Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/37/8793\" title=\"picture 2\">",
"      Type I MPGN EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/6/27753\" title=\"picture 3\">",
"      Transplant glomerulopathy EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31114?source=related_link\">",
"      Hepatitis C virus infection in patients on maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34088?source=related_link\">",
"      Membranous nephropathy and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_53_3929="Pathogenesis of osteoporosis";
var content_f3_53_3929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3929/contributors\">",
"     Stavros C Manolagas, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3929/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3929/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/53/3929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4206911\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fractures. Throughout life, older bone is periodically resorbed by osteoclasts at discrete sites and replaced with new bone made by osteoblasts. This process is known as remodeling. Remodeling is orchestrated and targeted to a particular site that is in need for repair by osteocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/1\">",
"     1",
"    </a>",
"    ]. An oversupply of osteoclasts relative to the need for remodeling or an undersupply of osteoblasts relative to the need for cavity repair are the seminal pathophysiological changes in osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of bone mass accrued by an individual reaches a peak by the third decade of life. Low peak bone mass probably contributes to the development of osteoporosis later in life. However, old age, sex steroid deficiency, lipid oxidation, decreased physical activity, use of glucocorticoids, and a propensity to fall are the most critical determinants of increased fracture risk.",
"   </p>",
"   <p>",
"    This topic will address each of these pathogenetic factors and, when it is known, how they interact with each other. Bone remodelling and osteoporotic fracture risk assessment are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15652863\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fractures. Although osteoporosis (a term used to define decreased bone mass per unit volume of anatomical bone) has become synonymous with decreased bone mineral density (BMD), this feature is not always present. Small bone size, unfavorable macro-architecture (eg, increased length of the femoral neck), disrupted micro-architecture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72620 \" href=\"UTD.htm?16/9/16529\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51633 \" href=\"UTD.htm?8/38/8808\">",
"     figure 1",
"    </a>",
"    ), cortical porosity, compromised quality of the material, and decreased viability of osteocytes (former osteoblasts buried within mineralized bone that sense and respond to changes in mechanical forces) are some other factors contributing to decreased strength.",
"   </p>",
"   <p>",
"    The diagnosis of osteoporosis or estimates of the risk for developing it in the future rely almost exclusively on measures of bone mass by imaging studies such as dual energy x-ray absorptiometry (DXA) (",
"    <a class=\"graphic graphic_table graphicRef74190 \" href=\"UTD.htm?11/28/11723\">",
"     table 1",
"    </a>",
"    ) and quantitative CT. These measures are fairly good clinical surrogates, but it is important to remember that the disease is bone fragility,",
"    <em>",
"    </em>",
"    and",
"    <em>",
"    </em>",
"    decreased BMD on DXA is just one of many risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341616\">",
"    <span class=\"h1\">",
"     PEAK BONE MASS ACQUISITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peak bone mass is the maximum bone mass achieved in life. The time of peak bone mass is not known with certainty, but probably occurs in the third decade of life in most individuals, with differences in timing due to genetic, hormonal, and environmental variables and to skeletal site (type of bone) and method of BMD measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14954217\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A portion of the variation in BMD among humans has a genetic basis. Genome-wide association studies have so far identified approximately 80 genetic loci that influence BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A remarkable number of these loci are involved in some aspect of",
"    <span class=\"nowrap\">",
"     Wnt/",
"    </span>",
"    of",
"    <span class=\"nowrap\">",
"     Wnt/&beta;-catenin",
"    </span>",
"    signaling, the",
"    <span class=\"nowrap\">",
"     RANK/RANKL/OPG",
"    </span>",
"    axis, or in mesenchymal cell differentiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The contribution of individual genetic variants, however, is small, and of the total variance in BMD only a small percentage is explained by variants of genes identified. To date, there are no genome-wide association studies on fracture or BMD loss. Therefore, it remains unclear whether the same genes that determine BMD also affect the rate of bone loss with advancing age or the risk of fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14954224\">",
"    <span class=\"h2\">",
"     Ethnic variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;African Americans have higher and Asian Americans have lower BMD than whites, and African Americans have lower fracture rates at many skeletal sites, including hip, clinical vertebral, upper and lower appendages. Hispanics and Asian Americans also have lower hip fracture rates than whites and the difference for Hispanics may depend on skeletal site. Importantly, BMD differences tend to be reduced in magnitude or removed if adjusted for body size differences [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14954231\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquisition of optimal bone mass is largely a reflection of increases in body size and skeletal loads mainly arising from muscle forces actuating bony levers such that limb muscle mass should be a reasonable measure of skeletal load. As children grow they gain both body weight and muscle mass, with increasing muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/7\">",
"     7",
"    </a>",
"    ]. Optimizing bone strength during this time has an impact on future risk of fracture. Unfavorable body composition during sexual maturation may result in sub-optimal bone strength in both early adulthood and later life. Nevertheless, peak muscle growth occurs before peak in bone growth and bone growth is not driven by muscle growth. Therefore, the importance of the muscle bone unit (MBU) for bone acquisition remains unclear.",
"   </p>",
"   <p>",
"    Physical activity during childhood augments bone mass and density, but preservation of the increased BMD requires continued physical activity. Conversely, chronic diseases during childhood pose numerous threats to bone health, resulting in either immediate fragility fractures or subsequent fractures in adulthood caused by suboptimal peak bone mass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/8\">",
"     8",
"    </a>",
"    ]. Risk factors for impaired bone accrual in such children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor growth",
"     </li>",
"     <li>",
"      Delayed maturation",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Muscle deficits",
"     </li>",
"     <li>",
"      Decreased physical activity",
"     </li>",
"     <li>",
"      Chronic inflammation",
"     </li>",
"     <li>",
"      Medications such as glucocorticoids",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341623\">",
"    <span class=\"h1\">",
"     OLD AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both women and men the balance between bone formation and resorption becomes progressively negative with advancing age (",
"    <a class=\"graphic graphic_figure graphicRef72007 \" href=\"UTD.htm?29/41/30354\">",
"     figure 2",
"    </a>",
"    ). Age-related bone loss begins immediately after peak bone mass",
"    <strong>",
"    </strong>",
"    for either sex, but most bone loss occurs after age 65. Men, however, are less likely to develop osteoporosis than women for two reasons. First, they gain more bone during puberty, and second, they lose less bone during aging because, unlike women, men do not experience an abrupt loss of estrogens. Elderly residents in long-term care have the greatest risk. Eighty-five percent of nursing home women over age 80 have osteoporosis. Hip and nonvertebral fractures in elderly residents of nursing homes are 2.5 to 3.5 times more common than in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most fractures after age 65 occur at predominantly cortical sites. High resolution peripheral CT of the radius and post-mortem femurs of women between ages 50 and 80 years has revealed that most bone loss in old age is the result of increased intracortical porosity (",
"    <a class=\"graphic graphic_figure graphicRef64827 \" href=\"UTD.htm?35/44/36549\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Besides its effects on bone mass, aging increases the risk of fractures, independently of bone mass, as highlighted by evidence that for the same BMD, a 20-year increase in age is accompanied by a fourfold increase in fracture risk (",
"    <a class=\"graphic graphic_figure graphicRef72007 \" href=\"UTD.htm?29/41/30354\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/11\">",
"     11",
"    </a>",
"    ]. Consistent with this, human cadaveric specimens demonstrate significant declines in whole bone strength with age, with younger specimens being three to 10-fold stronger than older specimens. Furthermore, population-based studies with 3D-QCT imaging have demonstrated significantly greater declines in vertebral compressive strength over life in women than men (-43 versus -31 percent). Declines in femoral strength in a sideways fall configuration are also significantly greater in women than men (-55 versus -39 percent) and exceed the declines in femoral BMD (-26 and -21 percent for women and men, respectively). In addition, cortical porosity increases by 176 percent and 259 percent from 20 to 90 years of age (",
"    <a class=\"graphic graphic_figure graphicRef64827 \" href=\"UTD.htm?35/44/36549\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Muscle strength and power decline 10 to 20 percent per decade after age 50. These declines obviously impact the risk of falls, and perhaps the severity of falls, but may also influence loads applied to vertebral bodies during daily activities. The influence of muscle strength on vertebral body compressive forces depends on the activity being performed. Vertebral compressive forces may remain unchanged, decrease, or greatly increase with reduced muscle strength. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8393?source=see_link\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link&amp;anchor=H651654#H651654\">",
"     \"Vitamin D and extraskeletal health\", section on 'Falls'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxidative stress (OS) is a shared mechanism of the pathogenesis of several degenerative disorders associated with aging, including osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. An increase in reactive oxygen species (ROS) has been implicated in the decreased bone formation associated with advancing age, as well as the increased resorption associated with estrogen deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/13\">",
"     13",
"    </a>",
"    ]. In line with this evidence, increased ROS production in osteoblasts stimulates apoptosis and decreases bone formation. In addition, ROS are a critical requirement for RANKL-induced osteoclast generation, activation, and survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341630\">",
"    <span class=\"h1\">",
"     SEX STEROID DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen or androgen deficiency causes loss of bone associated with an increase in the bone remodeling rate, increased osteoclast and osteoblast numbers, and increased resorption and formation, albeit unbalanced. Conversely, estrogens or androgens decrease bone resorption, restrain the rate of bone remodeling, and help to maintain a focal balance between bone formation and resorption. These effects are the result of hormonal influences on the birth rate of osteoclast and osteoblast progenitors in the bone marrow, as well as pro-apoptotic effects on osteoclasts and anti-apoptotic effects on mature osteoblasts and osteocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/2,3,13\">",
"     2,3,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15652976\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of cortical bone loss in women is closely tied to estrogen deficiency, attesting to the adverse effect of estrogen deficiency on skeletal homeostasis and its contribution to the age-associated bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/14\">",
"     14",
"    </a>",
"    ]. However, a significant proportion of trabecular bone loss throughout life is age-related and estrogen-independent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    The age-dependent loss of trabecular bone in the spine accelerates after the menopause, as does the rate of fractures at the wrist, spine, and hip. Between menopause and the age of 75, women lose approximately 22 percent of their total body bone mineral. It has been estimated that of this, 13.3 percent is due to aging and 7.75 percent is due to estrogen deprivation. In the femoral neck, 14 percent of the loss is &ldquo;age-related&rdquo; and only 5.3 percent because of estrogen deprivation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accelerated phase of cancellous (trabecular) bone loss caused by menopause results predominantly from trabecular perforation and loss of connectivity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72620 \" href=\"UTD.htm?16/9/16529\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51633 \" href=\"UTD.htm?8/38/8808\">",
"     figure 1",
"    </a>",
"    ). This phase is followed a few years later by a phase of slower bone loss that primarily affects cortical sites. The slower phase occurs in both women and men and is associated with a decrease in osteoblast number and bone formation rate and reduced number of trabeculae. In line with this, decreased wall width, the hallmark of decreased osteoblast work output, is the most consistent histological finding in elderly women and men with osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The dissimilarity of the effects of acute estrogen deficiency (as in menopause) and prolonged estrogen deficiency (as in elderly osteoporotic females) indicates that the effects of loss of estrogens are drastically modified and perhaps overridden by aging mechanisms intrinsic to bone.",
"   </p>",
"   <p>",
"    Estrogen deficiency may also contribute to the development of osteoporosis in men [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Estrogens derived from androgen aromatization and acting via the ER are important for skeletal homeostasis in men, as evidenced by bone abnormalities in men with estrogen receptor or aromatase mutations, as well as results of short-term clinical experimentation with administration of aromatase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, several clinical studies show correlation between a decrease in bioavailable estradiol, but not testosterone, and bone mass in elderly men [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast to the female-only effect of ER&alpha; deletion from osteoclasts, ER&alpha; deletion from osteoblast progenitors causes a decrease in cortical bone mass in both females and male mice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/22\">",
"     22",
"    </a>",
"    ]. Therefore, if estrogen deficiency contributes to male osteoporosis, its adverse effect may be limited to cortical bone and result from the loss of cell autonomous effects of estrogens favoring osteoblast formation. A favorable effect of estrogen on osteoblast could be due to the protection of osteoblast progenitors from the adverse effects of reactive oxygen species (ROS) and the generation of ROS and the attenuation of mature osteoblast and osteocyte apoptosis.",
"   </p>",
"   <p>",
"    However, it remains unknown whether, and to which extent, small differences of estrogen levels in the circulation contribute to changes of bone markers or BMD in elderly males, especially as similar small differences do not seem to cause BMD differences in premenopausal or perimenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/23\">",
"     23",
"    </a>",
"    ]. More important, whereas the accelerated cancellous (trabecular) bone loss caused by estrogen deficiency at menopause results predominantly from trabecular perforation and loss of connectivity, the later phase of slower bone loss that occurs in both elderly women and men primarily affects cortical sites and is associated with a decrease in osteoblast number and bone formation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/24\">",
"     24",
"    </a>",
"    ]. Additionally, bone loss in elderly men is associated with trabecular thinning rather than perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15652983\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens are critical for the homeostasis of the male skeleton in humans as evidenced by the low bone mass of men with idiopathic hypogonadotropic hypogonadism or complete androgen insensitivity syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32473?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiology of osteoporosis in men\", section on 'The role of hormones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cell autonomous effects of estrogens on osteoclasts mediated via the estrogen receptor &alpha; (ER&alpha;) account for most, if not all, the anti-resorptive properties of estrogens on the female, but not the male, mouse skeleton [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This evidence indicates that the protective effect of androgens on trabecular bone cannot be the result of ER&alpha;-mediated action of aromatized androgens. The non-aromatizable androgen dihydrotestosterone prevents orchidectomized-induced loss of trabecular bone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, trabecular number is preserved in men with homozygous loss of function mutation of ER&alpha;, indicating that the androgen receptor (AR) can preserve trabecular number in the absence of the ER&alpha; [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/30\">",
"     30",
"    </a>",
"    ]. Hence, to the extent that male osteoporosis is the result of an increase in bone resorption resulting from sex steroid deficiency, this can only result from a decrease in androgen, not estrogen, status.",
"   </p>",
"   <p>",
"    Thus, it is uncertain how much of the osteoporosis in older men results from aging as opposed to sex steroid deficiency, and of the hormonal component how much is due to true estrogen versus androgen deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a decrease in bioavailable estradiol as opposed to testosterone or dihydrotestosterone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341638\">",
"    <span class=\"h1\">",
"     LYMPHOCYTES AND CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase of reactive oxygen species (ROS) in the bone marrow in both aging and estrogen deficiency has been associated with expansion of T and B lymphocytes, NF-kB activation, and increased production of osteoclastogenic cytokines, including IL-1, IL-6, IL-7, TNF, prostaglandin E2, M-CSF, and RANKL. Conversely, estrogens or non-aromatizable androgens decrease NF-kB activation and cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The extent to which the effects of estrogens (or androgens) on T and B lymphocytes and cytokines (as opposed to direct effects on bone cells) contribute to the overall anti-resorptive effects of sex steroids and the role of these changes to the development of osteoporosis remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341645\">",
"    <span class=\"h1\">",
"     DECREASED OSTEOCYTE VIABILITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4206845\">",
"    <span class=\"h2\">",
"     Role of osteocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteocytes are former osteoblasts entombed in the mineralized matrix. In contrast to osteoclasts and osteoblasts, which are relatively short-lived and transiently present only on a small fraction of the bone surface, osteocytes are deployed throughout the skeleton, are far more abundant than either osteoclasts (1000 times) or osteoblasts (10 times), are long-lived, and their death is dependent on the age of the bone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteocytes choreograph the remodeling process on the bone surface by virtue of their ability to sense effete bone and direct the homing of osteoclasts to the site that is in need of remodeling. Indeed, osteocytes are the essential sources of the RANKL that controls bone remodeling, indicating that the cells best able to detect the need for matrix removal directly control the process [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/1\">",
"     1",
"    </a>",
"    ]. Moreover, osteocyte RANKL is responsible for the bone loss associated with mechanical unloading. In addition to RANKL, osteocytes are the source of the Wnt antagonist sclerostin, a limiting factor for osteoblast generation and bone mass accrual that mediates the homeostatic adaptation of bone to mechanical loading [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, osteocytes control and modify the mineralization of the matrix produced by osteoblasts by secreting factors such as MEPE and the phosphaturic hormone FGF23 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteocyte death increases in prevalence with age and is dependent on the age of the bone, not on the age of the subject. Osteocyte death is followed by hypermineralization of perilacunar bone and later by filling of canaliculi with mineralized connective tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/39\">",
"     39",
"    </a>",
"    ]. These changes, collectively referred to as micropetrosis, probably lead to increased brittleness of bone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/40\">",
"     40",
"    </a>",
"    ]. In deep bone, total lacunar density is lower than in superficial bone and falls substantially with age, so that micropetrosis, the only process that could lead to obliteration of lacunae, occurs in cancellous as well as in cortical bone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/41\">",
"     41",
"    </a>",
"    ]. There is a close spatial relationship between empty lacunae and microscopic fatigue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/42\">",
"     42",
"    </a>",
"    ], but it is unclear which occurs first, although both are the expected consequences of excessive bone age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4206838\">",
"    <span class=\"h2\">",
"     Age-related decline in osteocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age-related decline in osteocyte number is accompanied by reduced bone strength [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/31,43\">",
"     31,43",
"    </a>",
"    ]; several mechanisms likely contribute to this relationship. First, reduced osteocyte density in central cancellous bone is associated with increased surface remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/44\">",
"     44",
"    </a>",
"    ], which is an independent contributor to bone fragility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/45\">",
"     45",
"    </a>",
"    ]. Second, there is disruption of signals necessary for microdamage repair [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/46\">",
"     46",
"    </a>",
"    ]; these signals may be released during or shortly after osteocyte apoptosis, but if the osteocyte is already dead, such signals cannot be generated. Third, and probably most important, osteocyte death leads to a decline in bone vascularity and hydration, which reduces bone strength by mechanisms not yet fully understood, but which probably include changes in crystallinity and promotion of micropetrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/40,47\">",
"     40,47",
"    </a>",
"    ]. Conversely, protection of osteocytes from the adverse effect of aging on their apoptosis maintains bone crystallinity, vasculature volume, circulation of interstitial fluid, and strength.",
"   </p>",
"   <p>",
"    Oxidative stress, hypoxia, glucocorticoid excess, estrogen loss, changes in the perilacunar matrix, and cytokines are among the factors implicated for the increased osteocyte death with age. Under stress conditions, osteocytes deploy a self preservation mechanism called autophagy. Autophagy promotes resistance of osteocytic cells to oxidative stress-induced apoptosis, while expression of autophagy-related genes in bone declines with age. Moreover, mice lacking autophagy in osteocytes due to ATG7 deletion have low bone mass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/48\">",
"     48",
"    </a>",
"    ]. Therefore, compromised osteocyte autophagy may also contribute to the adverse effects of aging on the skeleton.",
"   </p>",
"   <p>",
"    Mechanical strain is a requirement of osteocyte viability and physiological levels of mechanical strain prevent apoptosis of cultured osteocytic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/49\">",
"     49",
"    </a>",
"    ]. Conversely, reduced mechanical forces with unloading increase the prevalence of osteocyte apoptosis, followed by bone resorption and loss of bone mineral and strength [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, reduced physical activity in old age, bed rest, or space flight invariably leads to bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteocytes are cellular targets of estrogen and androgen action. Estrogens or androgens inhibit osteoblast and osteocyte apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Conversely, estrogen or androgen deficiency increases the prevalence of osteocyte apoptosis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/54\">",
"     54",
"    </a>",
"    ], rats [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/55\">",
"     55",
"    </a>",
"    ], and mice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/53\">",
"     53",
"    </a>",
"    ]. It has been postulated that mechanical stain, perceived by a hypothetical skeletal mechanostat, leads to changes in bone remodeling in order to adjust bone mass to a level that is appropriate for the current ambient mechanical forces [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/56\">",
"     56",
"    </a>",
"    ]. It is also hypothesized that estrogen decreases the minimum effective strain necessary to initiate bone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/57\">",
"     57",
"    </a>",
"    ]. In support of this hypothesis, estrogens and exercise may exert additive effect on bone mass in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, the increased bone formation that normally occurs in response to mechanical loading is diminished in the estrogen deficient state in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/58\">",
"     58",
"    </a>",
"    ]. Evidence for a role of the estrogen receptor in the pro-survival effect of mechanical strain on osteocytes is consistent with the poor osteogenic response to loading exhibited by mice lacking the estrogen receptors &alpha; or &beta; [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/59\">",
"     59",
"    </a>",
"    ]. Increased osteocyte apoptosis following sex steroid deficiency could also affect bone mass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/1,36,60\">",
"     1,36,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341652\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID EXCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous or pharmacologic glucocorticoid excess is a common cause of osteoporosis. Unlike the postmenopausal form of the disease, but similar to the osteoporosis of old age, the rate of remodeling is low and the predominant abnormality is decreased bone formation. In addition, glucocorticoid excess, similar to aging, decreases bone strength disproportionately to its adverse effect on bone mass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/61\">",
"     61",
"    </a>",
"    ]. Glucocorticoid-induced osteoporosis frequently presents with fractures of the spine, ribs, and hip as early as three months following the initiation of long-term therapy and before any detectable decline on bone mass. This clearly suggests that pathologic changes other than decreased BMD are the cause of the increased fragility in this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The deleterious effects of glucocorticoid excess on bone result from direct effects on osteoblasts, osteocytes, and osteoclasts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/62-65\">",
"     62-65",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    This is a departure from earlier ideas that the adverse effects of glucocorticoids on bone are secondary to effects on calcium handling and the production of PTH or gonadal steroids. Indeed, glucocorticoid excess directly suppresses osteoblastogenesis, strongly and rapidly stimulates osteoblast and osteocyte apoptosis, and prolongs the lifespan of osteoclasts. Changes in the production of local growth factors, including insulin-like growth factors (IGF) and their binding proteins, and Wnt-&beta; catenin signaling may contribute.",
"   </p>",
"   <p>",
"    Glucocorticoid-induced loss of bone strength results in part from increased death of osteocytes and decreased skeletal hydration. Endogenous glucocorticoid production and sensitivity to the effects of glucocorticoids increase with age, inexorably contributing to the effects of old age in the development of osteoporosis. Increased sensitivity to glucocorticoids is the result of increased bone expression of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1, the enzyme that activates glucocorticoids. In both aging and pharmacologic hyperglucocorticoidism, increased apoptosis of osteocytes can account for the loss of bone strength that occurs before the loss of bone mineral density and the mismatch between bone mineral density and the risk of fracture in patients with glucocorticoid-induced osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/47,66,67\">",
"     47,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specifically, in both aging and glucocorticoid excess, the volume of the bone vasculature and solute transport from the peripheral circulation to the lacunar-canalicular system is decreased, leading to decreased skeletal hydration. The molecular underpinning of these effects is decreased angiogenesis resulting from decreased VEGF production by",
"    <span class=\"nowrap\">",
"     osteoblasts/osteocytes,",
"    </span>",
"    as well as decreased VEGF action. These changes represent a chain of interconnected pathogenetic mechanisms as indicated by anatomical evidence that the cellular processes of osteocytes are in direct contact with the bone vasculature (",
"    <a class=\"graphic graphic_figure graphicRef73524 \" href=\"UTD.htm?26/52/27465\">",
"     figure 4",
"    </a>",
"    ). Together with evidence that dehydration of bone decreases strength, these new insights reveal that endogenous glucocorticoids increase skeletal fragility in old age as a result of cell autonomous effects on osteocytes leading to interconnected decrements in bone angiogenesis, vasculature volume, and osteocyte-lacunar-canalicular fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341659\">",
"    <span class=\"h1\">",
"     OXIDIZED LIPIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and epidemiologic studies, as well as studies in animals, indicate a link between osteoporosis, atherosclerosis, and cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Bone loss and vascular calcification progress in parallel with advancing age and aortic calcification is inversely related to bone density and directly related to fractures in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/70\">",
"     70",
"    </a>",
"    ]. Women in the highest quartile for increased atherosclerosis exhibit four times greater yearly bone loss than women in the lowest quartile. Lipid oxidation plays a critical role in the development of atherogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/71\">",
"     71",
"    </a>",
"    ]. OS resulting from increased lipid oxidation and aberrant Wnt signaling may provide a mechanistic explanation for this link [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3929/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14954202\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fractures. Although osteoporosis has become synonymous with decreased bone mineral density (BMD), this feature is not always present. Small bone size, unfavorable macro-architecture (eg, increased length of the femoral neck), disrupted micro-architecture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72620 \" href=\"UTD.htm?16/9/16529\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51633 \" href=\"UTD.htm?8/38/8808\">",
"     figure 1",
"    </a>",
"    ), cortical porosity (",
"    <a class=\"graphic graphic_figure graphicRef64827 \" href=\"UTD.htm?35/44/36549\">",
"     figure 3",
"    </a>",
"    ), compromised quality of the material, and decreased viability of osteocytes (former osteoblasts buried within mineralized bone that sense and respond to changes in mechanical forces) are some of the other factors contributing to decreased strength.",
"   </p>",
"   <p>",
"    Multiple mechanisms are responsible for the syndrome of increased bone fragility with advancing age that we inexactly term osteoporosis. Low peak bone mass probably contributes to the development of osteoporosis later in life. However, old age, sex steroid deficiency, lipid oxidation, decreased physical activity, use of glucocorticoids, and a propensity to fall are the most critical determinants of increased fracture risk. The prevailing pathogenetic factor most likely varies from one individual to the other, as it is the case with other multi-factorial diseases like hypertension. In addition, in the same individual, the disease mechanism(s) may change with time. Thus, an increase in bone resorption early after menopause may be followed by decreased bone formation later in a woman&rsquo;s life.",
"   </p>",
"   <p>",
"    With continuing advances in our understanding of this complex disease and technical innovations in genetics and proteomics, as well improved imaging approaches, it is reasonable to expect that in the near future we will have a meaningful re-classification based on pathogenetic factor(s), and perhaps individualization of treatment with pathogenetic factor-tailored drugs.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/1\">",
"      Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med 2011; 17:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/2\">",
"      Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/3\">",
"      Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002; 57:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/4\">",
"      Duncan EL, Danoy P, Kemp JP, et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet 2011; 7:e1001372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/5\">",
"      Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012; 44:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/6\">",
"      Looker AC, Melton LJ 3rd, Borrud LG, Shepherd JA. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. Osteoporos Int 2012; 23:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/7\">",
"      Crabtree NJ, Kibirige MS, Fordham JN, et al. The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 2004; 35:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/8\">",
"      Wetzsteon RJ, Kalkwarf HJ, Shults J, et al. Volumetric bone mineral density and bone structure in childhood chronic kidney disease. J Bone Miner Res 2011; 26:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/9\">",
"      Vu MQ, Weintraub N, Rubenstein LZ. Falls in the nursing home: are they preventable? J Am Med Dir Assoc 2006; 7:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/10\">",
"      Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010; 375:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/11\">",
"      Hui SL, Slemenda CW, Johnston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/12\">",
"      Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/13\">",
"      Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/14\">",
"      Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 2011; 26:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/15\">",
"      Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000; 15:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/16\">",
"      Parfitt AM, Villanueva AR, Foldes J, Rao DS. Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res 1995; 10:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/17\">",
"      Han ZH, Palnitkar S, Rao DS, et al. Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res 1997; 12:498.",
"     </a>",
"    </li>",
"    <li>",
"     Parfitt AM. Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis. In: Osteoporosis, 3rd Ed, Marcus R, Feldman D, Nelson D, Rosen C. (Eds), Elsevier, San Diego 2007. p.71.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/19\">",
"      Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/20\">",
"      Jones ME, Boon WC, McInnes K, et al. Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab 2007; 3:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/21\">",
"      Santen RJ, Brodie H, Simpson ER, et al. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009; 30:343.",
"     </a>",
"    </li>",
"    <li>",
"     Almeida MJ, Ambrogini E, Martin Millan M, et al. ERa deletion in mesenchymal progenitors or mature osteoblasts decreases cortical bone thickness and increases apoptosis, respectively. J Bone Miner Res 2010; 25:S36, abstract # 1113. file://onlinelibrary.wiley.com/doi/10.1002/jbmr.5650251301/pdf (Accessed on September 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/23\">",
"      Sowers MR, Greendale GA, Bondarenko I, et al. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 2003; 14:191.",
"     </a>",
"    </li>",
"    <li>",
"     Parfitt AM. The two-stage concept of bone loss revisited. Triangle 1992; 31:99.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/25\">",
"      Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008; 358:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/26\">",
"      Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/27\">",
"      Martin-Millan M, Almeida M, Ambrogini E, et al. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 2010; 24:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/28\">",
"      Vanderschueren D, Van Herck E, Suiker AM, et al. Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology 1992; 130:2906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/29\">",
"      Vandenput L, Boonen S, Van Herck E, et al. Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 2002; 17:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/30\">",
"      Smith EP, Specker B, Bachrach BE, et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab 2008; 93:3088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/31\">",
"      Almeida M, Han L, Martin-Millan M, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007; 282:27285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/32\">",
"      Almeida M, Han L, Ambrogini E, et al. Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens. Mol Endocrinol 2010; 24:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/33\">",
"      Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006; 116:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/34\">",
"      Lee SK, Kadono Y, Okada F, et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res 2006; 21:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/35\">",
"      Manolagas SC, Parfitt AM. What old means to bone. Trends Endocrinol Metab 2010; 21:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/36\">",
"      Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22:6267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/37\">",
"      Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci 2007; 1116:281.",
"     </a>",
"    </li>",
"    <li>",
"     Manolagas SC. Choreography from the tomb: An emerging role of dying osteocytes in the purposeful, and perhaps not so purposeful, targeting of bone remodeling. BoneKey Osteovision 2006; 3:5. file://www.nature.com/bonekey/knowledgeenvironment/2006/0601/bonekey20060193/full/bonekey20060193.html (Accessed on September 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/39\">",
"      FROST HM. In vivo osteocyte death. J Bone Joint Surg Am 1960; 42-A:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/40\">",
"      FROST HM. Micropetrosis. J Bone Joint Surg Am 1960; 42-A:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/41\">",
"      Qiu S, Rao DS, Palnitkar S, Parfitt AM. Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone. Bone 2002; 31:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/42\">",
"      Qiu S, Rao DS, Fyhrie DP, et al. The morphological association between microcracks and osteocyte lacunae in human cortical bone. Bone 2005; 37:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/43\">",
"      Qiu S, Rao DS, Palnitkar S, Parfitt AM. Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res 2003; 18:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/44\">",
"      Qiu S, Rao DS, Palnitkar S, Parfitt AM. Relationships between osteocyte density and bone formation rate in human cancellous bone. Bone 2002; 31:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/45\">",
"      Heaney RP. Is the paradigm shifting? Bone 2003; 33:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/46\">",
"      Cardoso L, Herman BC, Verborgt O, et al. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 2009; 24:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/47\">",
"      Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010; 9:147.",
"     </a>",
"    </li>",
"    <li>",
"     Zhao H, Xiong,J, Onal,M, Cazer,P, Weinstein R., Manolagas S., O'Brien C. Osteocyte autophagy declines with age in mice and suppression of autophagy decreases bone mass. J Bone Min Res 2011",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/49\">",
"      Plotkin LI, Mathov I, Aguirre JI, et al. Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs. Am J Physiol Cell Physiol 2005; 289:C633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/50\">",
"      Aguirre JI, Plotkin LI, Stewart SA, et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 2006; 21:605.",
"     </a>",
"    </li>",
"    <li>",
"     Marcus R. Mechanisms of exercise effects on bone. In: Principles of bone biology, 2nd, Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego 2002. Vol 1, p.1477.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/52\">",
"      Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/53\">",
"      Kousteni S, Chen JR, Bellido T, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002; 298:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/54\">",
"      Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 1997; 82:3128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/55\">",
"      Tomkinson A, Gevers EF, Wit JM, et al. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998; 13:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/56\">",
"      Frost HM. The mechanostat: a proposed pathogenic mechanism of osteoporoses and the bone mass effects of mechanical and nonmechanical agents. Bone Miner 1987; 2:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/57\">",
"      Schiessl H, Frost HM, Jee WS. Estrogen and bone-muscle strength and mass relationships. Bone 1998; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/58\">",
"      Lee K, Jessop H, Suswillo R, et al. Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature 2003; 424:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/59\">",
"      Lee KC, Jessop H, Suswillo R, et al. The adaptive response of bone to mechanical loading in female transgenic mice is deficient in the absence of oestrogen receptor-alpha and -beta. J Endocrinol 2004; 182:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/60\">",
"      O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/61\">",
"      Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48:3224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/62\">",
"      Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/63\">",
"      Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85:2907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/64\">",
"      Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/65\">",
"      Jia D, O'Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006; 147:5592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/66\">",
"      Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/67\">",
"      Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res 2000; 15:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/68\">",
"      Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/69\">",
"      Parhami F, Tintut Y, Beamer WG, et al. Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res 2001; 16:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/70\">",
"      Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89:4246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/71\">",
"      Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/72\">",
"      Manolagas SC, Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007; 21:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3929/abstract/73\">",
"      Almeida M, Ambrogini E, Han L, et al. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 2009; 284:27438.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2044 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3929=[""].join("\n");
var outline_f3_53_3929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14954202\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4206911\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15652863\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341616\">",
"      PEAK BONE MASS ACQUISITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14954217\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14954224\">",
"      Ethnic variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14954231\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341623\">",
"      OLD AGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341630\">",
"      SEX STEROID DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15652976\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15652983\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341638\">",
"      LYMPHOCYTES AND CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341645\">",
"      DECREASED OSTEOCYTE VIABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4206845\">",
"      Role of osteocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4206838\">",
"      Age-related decline in osteocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341652\">",
"      GLUCOCORTICOID EXCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341659\">",
"      OXIDIZED LIPIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14954202\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2044\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2044|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/9/16529\" title=\"diagnostic image 1\">",
"      CT image of cancellous bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2044|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/38/8808\" title=\"figure 1\">",
"      Histological image of cortical and cancellous bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/41/30354\" title=\"figure 2\">",
"      BMD and fracture risk by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/44/36549\" title=\"figure 3\">",
"      Age-related bone loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/52/27465\" title=\"figure 4\">",
"      Connection between osteocytes and blood vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2044|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/28/11723\" title=\"table 1\">",
"      Osteopenia and osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_53_3930="Management of gastrointestinal lymphomas";
var content_f3_53_3930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of gastrointestinal lymphomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3930/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3930/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3930/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3930/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/53/3930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/53/3930/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/53/3930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary gastrointestinal (GI) non-Hodgkin lymphoma (NHL) is a heterogeneous group of B and T cell lymphoid malignancies. The clinical features, management, and prognosis of these lymphomas differ from lymphomas of lymph node origin.",
"   </p>",
"   <p>",
"    Because GI NHLs are rare, optimal treatments have not been defined. Current recommendations are primarily based upon data from case series, rather than large, randomized clinical trials. The various treatment strategies for each of the predominant types of GI NHL will be reviewed here. The clinical manifestations and diagnosis of these tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a diagnosis of GI lymphoma is confirmed, a pretreatment evaluation determines the extent of disease. The specific tests included depend partly upon the location of the tumor. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, HIV serology, chemistries with liver and renal function, electrolytes, and lactate dehydrogenase (LDH). Patients should undergo serologic testing for hepatitis B and hepatitis C. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the chest, abdomen and pelvis should be performed to evaluate for distant disease. The use of positron emission tomography (PET) is controversial except in cases of diffuse large B cell lymphoma (DLBCL) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An endoscopic evaluation is performed based upon the site of disease. Patients with gastric lymphoma should undergo an esophagogastroduodenoscopy. Some institutions also perform endoscopic ultrasound to further determine the depth of invasion and involvement of perigastric lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/4\">",
"       4",
"      </a>",
"      ]. Patients with intestinal lymphoma should undergo endoscopy to evaluate the site of disease.",
"     </li>",
"     <li>",
"      Patients with gastric lymphoma should be tested for Helicobacter pylori (H pylori), which can be detected by histologic specimen, biopsy urease test, urea breath test, stool antigen test, or serology in the vast majority of gastric MALT lymphoma (90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) testing for t(11;18) should be performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation of nutritional and performance status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link\">",
"       \"The role of parenteral and enteral/oral nutritional support in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy and aspirate should be performed on all patients.",
"     </li>",
"     <li>",
"      Additional studies (eg, magnetic resonance imaging (MRI) of the orbit) should be reserved for select patients who have findings on history",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physical examination concerning for involvement of additional sites.",
"     </li>",
"     <li>",
"      Men and women with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ann Arbor staging system used for most lymphomas is considered to be inadequate for the staging of GI lymphoma since it does not incorporate information on the depth of tumor invasion known to affect prognosis. Several other staging systems have been proposed, but with limited consensus. The lack of a uniform staging system has hindered the direct comparison of clinical trials. The most widely accepted staging system is the Lugano staging system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Lugano staging system was developed to incorporate measures of distant nodal involvement (",
"      <a class=\"graphic graphic_table graphicRef65686 \" href=\"UTD.htm?32/31/33275\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/6\">",
"       6",
"      </a>",
"      ]. Early (stage",
"      <span class=\"nowrap\">",
"       I/II)",
"      </span>",
"      disease includes a single primary lesion or multiple, noncontiguous lesions confined to the GI tract that may have nodal involvement. There is no stage III in the Lugano system. Advanced (stage IV) disease displays disseminated extranodal involvement or concomitant supra-diaphragmatic nodal involvement.",
"     </li>",
"     <li>",
"      A modified TNM staging system, also called the Paris staging system, modeled after the staging of gastric adenocarcinoma, is not as commonly used [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the purposes of this review, we will use the Lugano staging system to describe the treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GASTRIC MALT LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal marginal zone B cell (MALT) lymphoma, previously called MALT-type lymphoma or MALT lymphoma, is one of the most common histologic types of gastric lymphoma. This is an indolent lymphoma that frequently presents with localized, early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/8\">",
"     8",
"    </a>",
"    ]. The treatment of gastric MALT lymphoma is dictated primarily by the presence or absence of a concomitant H pylori infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with early stage (Lugano",
"      <span class=\"nowrap\">",
"       I/II)",
"      </span>",
"      H pylori positive lymphoma are initially treated with H pylori eradication therapy.",
"     </li>",
"     <li>",
"      Patients without evidence of H pylori infection, H pylori eradication therapy failures, and patients with tumors that demonstrate the t(11;18) translocation are typically treated with local radiation therapy.",
"     </li>",
"     <li>",
"      Patients with advanced stage (Lugano IV) disease are treated with H pylori eradication therapy if they are H pylori positive and then generally observed until the development of symptoms at which time they undergo treatment with immunotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gastric resection is reserved for patients with complications such as perforation or obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/9-13\">",
"     9-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Early stage H pylori positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with gastric lymphoma present with early stage (Lugano",
"    <span class=\"nowrap\">",
"     I/II)",
"    </span>",
"    H pylori positive disease. There have been no randomized clinical trials comparing different treatment options in this population. Prospective single arm trials and retrospective series have evaluated the use of H pylori eradication, radiation therapy (RT), and surgery for these patients. Of these, H pylori eradication has emerged as the preferred treatment because of its low side effect profile and demonstrated efficacy. After initial therapy, patients must be monitored with serial endoscopies to evaluate for disease response and recurrence. Treatment failures should be treated with local RT administered with curative intent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     H pylori eradication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy aimed at the eradication of H pylori is the favored initial treatment for patients with early stage H pylori positive gastric MALT lymphoma. With this approach, 50 to 80 percent of patients with localized gastric MALT achieve a histologic complete remission (CR), which will be maintained long-term for the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/14-22\">",
"     14-22",
"    </a>",
"    ]. Of importance, tumors demonstrating the t(11;18) translocation are unlikely to respond to H pylori eradication and are candidates for alternative therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/20,23-27\">",
"     20,23-27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Early stage H pylori negative'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several small prospective, single-arm trials and larger retrospective series have evaluated the use of combinations of antibiotics and proton pump inhibitors as H pylori eradication therapy for the treatment of gastric MALT lymphoma. A comparison of these trials is limited by a lack of consensus regarding response evaluation and the definition of CR. The following is a summary of the results of these trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/14-22\">",
"     14-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost all patients were able to successfully eradicate the H pylori infection, but approximately 20 percent required a second course of H pylori directed therapy to do so.",
"     </li>",
"     <li>",
"      Histologic CR was achieved in 50 to 83 percent of patients.",
"     </li>",
"     <li>",
"      The median time from H pylori eradication to CR was 15 months, but ranged from five months to over three years.",
"     </li>",
"     <li>",
"      After a median follow-up of 6.8 years, one study reported disease relapse in 16 of 74 patients (22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In comparison, patients treated with radiation therapy (RT) almost always attain a CR and have lower relapse rates (less than 5 percent), but have a potential for more complications. Gastrectomy is associated with high morbidity and higher recurrence rates than seen with RT.",
"   </p>",
"   <p>",
"    As mentioned above, up to one-third of gastric MALT lymphomas will demonstrate the t(11;18) translocation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]; such patients have a very low chance of responding to H pylori eradication therapy. As an example, one study with a median follow-up of over five years, reported significantly lower rates of continuous CR following antibiotic treatment in tumors with t(11;18) when compared with those without this translocation (30 versus 77 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who have early stage H pylori positive gastric MALT lymphoma without t(11;18), we recommend initial H pylori eradication therapy rather than RT. There have been no comparisons of various H pylori eradication regimens in this setting and a choice among these depends upon availability and patient related factors such as penicillin allergy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether patients who achieve a CR should receive additional therapy has not been extensively studied. The available data suggest that no further treatment is required but patients should be followed closely. This was illustrated in a study of 231 patients with stage I MALT of whom 97 percent had successful eradication of H pylori after antibiotics and 59 percent (110 patients) achieved macroscopically normal gastric mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients who achieved a histologic CR were randomly assigned further treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    or observation. After a median follow-up of five years, there was no significant difference in progression-free survival (89 versus 79 percent) or overall survival (96 versus 93 percent), although the study may have been too small to detect a difference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients initially treated with H pylori eradication therapy need to be evaluated after the completion of treatment to determine whether the H pylori was successfully eradicated and whether there has been a tumor response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four to eight weeks after the completion of H pylori eradication therapy, urea breath testing should be performed to confirm eradication of infection. Up to 20 percent of patients will require a second H pylori eradication regimen to fully eliminate the infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link&amp;anchor=H27#H27\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\", section on 'Confirmation of eradication'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After successful eradication of H pylori, patients should undergo periodic upper endoscopy with multiple biopsies to evaluate for tumor response and monitor for relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. While this has not been formally studied, we typically perform endoscopy with biopsies every one to three months until a histologic complete response (CR) is attained, and then perform endoscopy every six months for at least the first two years and then as clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, there has been little consensus regarding what constitutes a CR of gastric MALT. The most commonly applied criteria, the Wotherspoon histological index (",
"    <a class=\"graphic graphic_table graphicRef78881 \" href=\"UTD.htm?38/25/39323\">",
"     table 2",
"    </a>",
"    ), were originally devised to differentiate between gastritis and MALT lymphoma at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/14\">",
"     14",
"    </a>",
"    ]. Using these criteria, patients who demonstrate grade 0 to 2 lesions are considered to have a histologic CR, while grade 3 lesions are classified as a partial response (PR). Another histological evaluation system, which requires prospective verification, defines a histological CR as a normal or empty lamina propria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrosis with absent or sparse plasmacytes and lymphoid cells in the lamina propria without lymphoepithelial lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While successful treatment with radiation usually results in the disappearance of B cell clonality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/32\">",
"     32",
"    </a>",
"    ], treatment with H pylori eradication therapy often demonstrates persistent B cell clonality on molecular studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/33\">",
"     33",
"    </a>",
"    ]. The ultimate clinical significance of persistent clonality in these treatment settings is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/19,33-35\">",
"     19,33-35",
"    </a>",
"    ]. As an example, a cooperative study of patients achieving histologic CR following eradication of H pylori has shown no significant difference in the rate of histologic relapse between those who did or did not achieve molecular remission [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/19\">",
"     19",
"    </a>",
"    ]. We reserve molecular testing for patients on clinical trials and define CR in clinical practice based upon histologic criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment failures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 30 percent of patients do not respond to H pylori eradication therapy or demonstrate relapse during follow-up. Histology should be reviewed carefully at this time to confirm the presence of MALT lymphoma and absence of more aggressive lymphomas, such as diffuse large B cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appropriate timing of second line therapy is complicated by the sometimes slow response to H pylori eradication therapy with attainment of CR taking up to three years. In general, we refer patients to a radiation oncologist if disease is still present after 12 to 18 months. Second line therapies are typically reserved for patients with histologic evidence of relapse following CR, progressive disease following a partial response, or those with no response or progressive disease after initial treatment.",
"   </p>",
"   <p>",
"    Patients with relapsed MALT lymphoma have five-year survival rates as high as 80 to 90 percent. Treatment options include localized radiation for disease limited to the stomach or perigastric nodes and single agent chemotherapy for those with Lugano stage IV disease. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Advanced stage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Early stage H pylori negative",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients with early stage (Lugano",
"    <span class=\"nowrap\">",
"     I/II)",
"    </span>",
"    gastric MALT lymphoma will not demonstrate infection with H pylori at the time of diagnosis. These patients should be treated with radiation therapy (RT) administered with curative intent. RT is also appropriate for patients with tumors that demonstrate the t(11;18) translocation that is typically unresponsive to H pylori eradication therapy. Other treatments, including immunotherapy, single agent chemotherapy, chemoimmunotherapy, and multiagent chemotherapy, are reserved for patients failing or recurring after RT and those with advanced stage disease (ie, Lugano stage IV). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Advanced stage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The data regarding these treatment options comes from retrospective studies and small, single agent prospective trials. There have been no clinical trials directly comparing these treatment strategies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy &mdash; Local RT (total dose of 25 to 30 Gy) results in high rates of overall and complete responses (100 and 98 percent, respectively) for early stage gastric MALT with no local relapses and five-year disease free and overall survival rates of 98 and 77 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. Toxicities are limited in duration and include anorexia, malaise, nausea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dyspepsia.",
"     </li>",
"     <li>",
"      Immunotherapy-based treatment &mdash; Single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      results in overall and complete response rates of approximately 77 and 46 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. When rituximab is combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , the overall response rate increases (85 to 100 percent), as do the associated toxicities, which are mainly hematologic, infectious, and allergic [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Similarly, the addition of rituximab to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      results in a higher complete remission rate and improved event-free survival at five years, but no apparent difference in overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/45\">",
"       45",
"      </a>",
"      ]. Rituximab therapy carries a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. The risk of hepatitis B reactivation is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Advanced stage'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Single agent chemotherapy agents that have been studied include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Daily oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      resulted in CR rates of approximately 75 percent with relapses seen in approximately 21 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/46\">",
"       46",
"      </a>",
"      ]. The most common toxicity was moderate leukopenia and an associated increased risk of infection. These agents do not appear to have activity in patients with t(11;18) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       Cladribine",
"      </a>",
"      , administered as an infusion in five-day cycles repeated every four weeks, resulted in a CR rate of 84 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/48\">",
"       48",
"      </a>",
"      ]. Toxicities were mainly hematologic (leukopenia and anemia) with associated infectious complications, including herpes zoster. Cladribine also appears to be effective in patients with t(11;18) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      has demonstrated overall and complete response rates of 48 and 31 percent, respectively, in patients with relapsed or refractory extranodal MALT, but toxicity limits its use in this population [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/50\">",
"       50",
"      </a>",
"      ]. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      side effects are fatigue (13 percent), neuropathic pain (10 percent), peripheral sensory neuropathy (13 percent), neutropenia (13 percent), and thrombocytopenia (13 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there have been case reports of tumor responses to H pylori eradication in H pylori negative patients, this is highly unusual and typically limited to patients with disease limited to the stomach [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/17,21,51\">",
"       17,21,51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who have early stage H pylori negative gastric MALT lymphoma or those with t(11;18), we suggest initial treatment with local RT rather than H pylori eradication therapy, immunotherapy, chemotherapy, or gastrectomy. This is principally due to the high complete response rates, low toxicity profile, and long-term remissions associated with this approach. Alternatively, a trial of H pylori eradication therapy may be considered for patients with disease limited to the stomach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Restaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform serial endoscopies at one and two years after completion of radiation therapy. If the patient is disease-free after two years, we do not perform further endoscopies unless new symptoms develop. As described above, there is no general consensus regarding the preferred response criteria. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Response evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Persistent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with early stage H pylori negative gastric MALT can achieve a complete remission (CR) with initial radiation therapy (RT). Those patients who fail to achieve a CR can be considered for treatment with single agent chemotherapy agents or immunotherapy as described in the section above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Initial therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who choose chemotherapy or immunotherapy for their initial therapy can be considered for RT if there is persistent disease or if they develop localized relapse. Those who progress despite single agent chemotherapy, immunotherapy, and RT can be considered for treatment regimens used for advanced stage disease. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Advanced stage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Advanced stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced stage (Lugano IV) gastric MALT are treated with H pylori eradication therapy if they are H pylori positive, and then generally observed until the development of symptoms at which time they undergo treatment with immunotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy. The choice of therapy at progression is not clearly defined and most data in this population come from retrospective series or extrapolation of data from other indolent NHL. Until more information is available on outcomes in this patient population, these patients are typically treated in a similar fashion to those with advanced stage follicular lymphoma. The treatment of advanced stage follicular lymphoma is presented in more detail separately, as the management of advanced stage non-gastric marginal zone lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of marginal zone (MALT) lymphoma\", section on 'Advanced (stage III-IV) disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NON-GASTRIC MALT LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-gastric MALT lymphomas are typically divided into the immunoproliferative small intestinal disease (IPSID) lymphoma, which secretes alpha heavy chains, and \"Western type\" MALT, which does not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Lymphoma of the small intestine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Non-IPSID non-gastric MALT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of non-gastric MALT lymphoma depends principally upon the stage of disease at diagnosis. More than one-third of patients with non-gastric MALT lymphoma will have advanced disease at the time of diagnosis.",
"   </p>",
"   <p>",
"    Limited stage MALT lymphoma is generally treated with local therapy. In comparison, more advanced disease is treated with immunotherapy or chemoimmunotherapy in a similar fashion to the more common indolent lymphoma, follicular lymphoma. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=see_link\">",
"     \"Treatment of marginal zone (MALT) lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of importance, patients with MALT lymphoma of any stage who demonstrate coexistent large cell lymphoma are treated as diffuse large B cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immunoproliferative small intestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoproliferative small intestinal MALT lymphomas (IPSID) are relatively rare, and few data are available for guiding treatment. Surgery is rarely indicated because intestinal involvement is generally diffuse. For patients who are diagnosed at an early stage, treatment with antibiotics, perhaps directed against Campylobacter jejuni or H pylori, may lead to regression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. The choice of antibiotic may be determined by culture results in patients with intestinal bacterial overgrowth and, in the absence of bacterial overgrowth, a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Most patients ultimately relapse and present with an aggressive high-grade histology. For such patients, radiation therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    combination chemotherapy combined with nutritional support are the mainstays of treatment. Five-year survival rates as high as 70 percent are seen in patients treated with combination chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    to control diarrhea and malabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The chemotherapy regimens used are dependent upon the histology of the aggressive lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFUSE LARGE B CELL LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;GI diffuse large B cell lymphoma (DLBCL) includes lesions previously called \"high-grade\" MALT lymphoma. It can occur anywhere along the GI tract and is the most common histology for primary gastric lymphoma, representing approximately 50 percent of cases. Compared with patients with low-grade lymphoma, these patients tend to have more systemic symptoms, a more advanced stage at diagnosis, and a worse prognosis. In one series of 114 patients, for example, those with DLBCL had lower rates of complete remission (68 versus 92 percent) and five-year overall survival (46 versus 75 percent) when compared with those with low-grade MALT lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options that have been evaluated in GI DLBCL include surgery, radiation therapy (RT), chemoimmunotherapy, H pylori eradication therapy, and combinations of the above. In general, most patients are treated with combination chemoimmunotherapy regimens used for non-GI DLBCL. A few patients may be candidates for a trial of H pylori eradication therapy. Surgery is reserved for patients with complications such as perforation or obstruction or intractable bleeding. This applies to both early stage and advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/9,59-62\">",
"     9,59-62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Early stage H pylori positive'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Retrospective analyses and uncontrolled prospective trials have had mixed results with some suggesting a benefit from surgery and others suggesting no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/9,59-64\">",
"     9,59-64",
"    </a>",
"    ]. A prospective trial of 589 patients with early stage primary gastric DLBCL randomly assigned therapy with surgery, surgery plus RT, surgery plus CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) chemotherapy, or CHOP chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/65\">",
"     65",
"    </a>",
"    ]. Ten-year event free survival rates for patients assigned to the four treatment arms were 28, 23, 82, and 92 percent, respectively. Late toxicity was more frequent and severe in patients undergoing surgery. This trial did not include treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -based chemotherapy or the use of adjuvant RT after chemotherapy.",
"   </p>",
"   <p>",
"    While some studies have found regression with antibiotics alone in limited stage gastric DLBCL, this approach has not been directly compared with the use of combination chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/18,66,67\">",
"     18,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An illustrative study included 16 patients with H pylori infection and stage IE gastric \"high-grade\" MALT lymphoma who received a brief antibiotic regimen as first line treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/67\">",
"       67",
"      </a>",
"      ]. Eradication of H pylori infection was achieved in 15 of the 16 patients. Gross and histologic tumor regression was evident in 10 patients at the first follow-up endoscopic examination; the remaining 6 patients were immediately referred for chemotherapy. At a median follow-up of 43 months, all 10 patients with responsive disease were alive and free of lymphoma, while 5 of the 6 non-responding patients achieved complete remission following CHOP chemotherapy.",
"     </li>",
"     <li>",
"      In a second, slightly larger prospective study of patients with low-grade MALT lymphoma accompanied by \"high-grade transformed\" disease, H pylori infection was eradicated with two weeks of antibiotic treatment in 22 of 24 patients, with resulting complete response in 14 of the 22 patients with H pylori eradication and in neither of the two patients with persistent H pylori infection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/18\">",
"       18",
"      </a>",
"      ]. After a median follow-up of five years, none of the 14 patients with antibiotic-responsive \"high-grade\" disease developed tumor recurrence following treatment with antibiotics alone.",
"     </li>",
"     <li>",
"      In a retrospective study, the vast majority of patients with stage",
"      <span class=\"nowrap\">",
"       IE/IIE",
"      </span>",
"      H pylori positive gastric de novo DLBCL (16 of 16 patients) or &ldquo;high-grade transformed&rdquo; MALT lymphoma (21 of 34 patients) achieved successful H pylori eradication with antibiotic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/68\">",
"       68",
"      </a>",
"      ]. Complete pathologic remission was attained in 11 patients (69 percent) with de novo DLBCL and 18 patients (56 percent) with transformed MALT after a median of two and five months, respectively. At a median follow-up of 7.7 years, none of the patients who had achieved a pathologic complete remission had relapsed. Similar results were seen in a small prospective trial of H pylori eradication in 16 patients with stage I H pylori positive gastric de novo DLBCL [",
"      <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most patients with GI DLBCL, we recommend the use of combination chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (ie, R-CHOP) with or without involved-field RT such as that used for other patients with limited stage DLBCL rather than treatment with surgery or H pylori eradication therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For a subset of patients with limited stage gastric DLBCL demonstrating a component of low grade MALT lymphoma and concomitant H pylori infection, a brief trial of H pylori eradication therapy is an acceptable alternative. This use of H pylori eradication therapy for limited stage gastric DLBCL is not universally accepted and requires very close monitoring for possible treatment failure. Prospective trials are needed to investigate this treatment in larger numbers of patients with gastric DLBCL before it can be recommended for the larger population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gastric perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original concern that patients with lymphomatous involvement of the stomach given chemotherapy may develop gastric perforation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding has not been confirmed in a number of comparative studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/9,13,59,70-73\">",
"     9,13,59,70-73",
"    </a>",
"    ]. Occasional patients may still require surgical consultation for bleeding, gastric outlet obstruction, or",
"    <span class=\"nowrap\">",
"     relapsed/resistant",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ENTEROPATHY-ASSOCIATED T CELL INTESTINAL LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteropathy-associated T cell intestinal lymphoma (EATL), which is most often a sequela of celiac disease, is almost always of high-grade histology; the prognosis is poor and is worse than that of other intestinal lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment consists of combination chemotherapy used for other aggressive T cell lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/75\">",
"     75",
"    </a>",
"    ]. Patients who are candidates for autologous hematopoietic cell transplantation (HCT) may benefit from HCT in first remission. The five-year overall survival rate with anthracycline-based chemotherapy alone is approximately 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. With HCT, case reports have suggested that some patients may achieve longer survival rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding the use of autologous HCT for EATL mostly come from case reports and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/79-83\">",
"     79-83",
"    </a>",
"    ]. A retrospective study of 26 patients with EATL treated with an intensive chemotherapy regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) followed by autologous HCT rescue reported rates of progression-free (PFS) and overall survival (OS) at five years of 52 and 60 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/82\">",
"     82",
"    </a>",
"    ]. Although a randomized trial is needed for a direct comparison, these rates are much higher than those expected from treatment with chemotherapy alone.",
"   </p>",
"   <p>",
"    For patients with EATL who have a good performance status and chemotherapy sensitive disease, we suggest treatment with intensive chemotherapy followed by autologous HCT rather than chemotherapy alone. Patients with EATL are usually malnourished at the time of diagnosis. In addition, intra-abdominal perforation, fistula formation, and infection frequently complicate management, especially in those who required surgical resection. Nutritional supplementation and vigorous control of infection are integral to any treatment program [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Given its association with celiac disease, patients should be maintained on a gluten-free diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98998264\">",
"    <span class=\"h1\">",
"     PRIMARY INTESTINAL FOLLICULAR LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary intestinal follicular lymphoma is a variant of FL characterized by lymphomatous disease pathologically consistent with follicular lymphoma confined to the intestine without lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/86\">",
"     86",
"    </a>",
"    ]. Primary follicular lymphoma of the duodenum (FL-D) has been proposed as a unique clinicopathologic entity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FL-I is a rare entity initially described in small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/87-95\">",
"     87-95",
"    </a>",
"    ]. The largest series included 63 patients with stage I FL-I of the small intestine diagnosed by endoscopic biopsy and followed for a median of 77 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/53/3930/abstract/87\">",
"     87",
"    </a>",
"    ]. Four general treatment strategies were used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Watch and wait &mdash; Of the 24 patients managed with serial endoscopies, seven experienced a complete remission (CR), 17 had stable disease, and two developed nodal follicular lymphoma. Both patients who developed nodal follicular are in CR after treatment with combination chemotherapy. None of these patients developed symptoms directly related to gastrointestinal involvement requiring intervention.",
"     </li>",
"     <li>",
"      Radiation therapy &mdash; All 19 patients treated with local radiation with a focal dose of 30 to 45.3 Gy and abdominal bath of 24.5 to 30 Gy attained a CR.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      monotherapy &mdash; Of the five patients who received rituximab alone, four had a CR, and one had stable disease.",
"     </li>",
"     <li>",
"      Chemotherapy with or without radiation &mdash; All eight patients who were treated with chemotherapy with or without radiation attained a CR. Three developed duodenal relapse. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiation of the small bowel is associated with chronic radiation enteritis manifested by malabsorption and diarrhea. This toxicity can be minimized by using a technique that avoids whole abdominal irradiation. For this technique, a radiopaque clip is placed by endoscopy at the location of the tumor and this clip is then used to identify and treat involved bowel plus a margin of normal tissue to 30 to 36 Gy. However, given the potential toxicity of radiation therapy and the indolent nature of FL-D, a watch-and-wait strategy is a reasonable alternative to radiation therapy in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link&amp;anchor=H18#H18\">",
"     \"Gastrointestinal toxicity of radiation therapy\", section on 'Chronic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANTLE CELL LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma involving the GI tract usually presents in older patients, often involving multiple sites throughout the GI tract (lymphomatous polyposis). Surgery has a relatively small role in the management, but may be of value in patients presenting with bowel obstruction or intractable bleeding. Systemic chemotherapy is the treatment of choice for advanced disease. However, if the tumor is localized (ie, clinical stage IAE), chemotherapy followed by radiation to 30 Gy may be curative. Lower dose radiation (eg, 15 to 20 Gy) can be very effective for the management of large abdominal masses in the palliative setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17402?source=see_link\">",
"     \"Initial treatment of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     BURKITT LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy is the mainstay of treatment of Burkitt lymphoma, but resection is often required to alleviate symptoms or avoid perforation during chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=see_link\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary gastrointestinal (GI) non-Hodgkin lymphoma (NHL) is a heterogeneous group of B and T cell lymphoid malignancies. The management of these lymphomas may differ from lymphomas of lymph node origin.",
"     </li>",
"     <li>",
"      The specific tests included in the pretreatment evaluation depend partly upon the location of the tumor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of gastric MALT (extranodal marginal zone B cell) lymphoma is dictated primarily by the disease stage and the presence or absence of a concomitant Helicobacter pylori infection:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have early stage H pylori positive gastric MALT lymphoma without t(11;18), we recommend initial H pylori eradication therapy rather than radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). A choice among H pylori eradication regimens depends upon availability and patient related factors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Early stage H pylori positive'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have early stage H pylori negative gastric MALT lymphoma or those with t(11;18), we suggest initial treatment with local RT rather than H pylori eradication therapy, immunotherapy, chemotherapy, or gastrectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Early stage H pylori negative'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced stage gastric MALT lymphoma we suggest treatment with H pylori eradication therapy if H pylori positive followed by observation until the development of symptoms at which time chemotherapy is initiated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Advanced stage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are evaluated after the completion of treatment to determine whether the H pylori was successfully eradicated (if appropriate) and whether there has been a tumor response. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Response evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients with GI diffuse large B cell lymphoma (DLBCL), we recommend the use of combination chemotherapy plus immunotherapy (eg, R-CHOP) such as that used for other patients with DLBCL with or without involved-field RT rather than treatment with surgery or H pylori eradication therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with enteropathy-associated T cell intestinal lymphoma who have a good performance status and chemotherapy sensitive disease, we suggest treatment with intensive chemotherapy followed by autologous HCT rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/1\">",
"      Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 2007; 79:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/2\">",
"      Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005; 16:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/3\">",
"      Hoffmann M, Kletter K, Becherer A, et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003; 64:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/4\">",
"      Fischbach W, Al-Taie O. Staging role of EUS. Best Pract Res Clin Gastroenterol 2010; 24:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/5\">",
"      Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998; 338:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/6\">",
"      Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/7\">",
"      Ruskon&eacute;-Fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas. Gut 2003; 52:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/8\">",
"      Musshoff K. [Clinical staging classification of non-Hodgkin's lymphomas (author's transl)]. Strahlentherapie 1977; 153:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/9\">",
"      Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19:3874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/10\">",
"      Coiffier B, Salles G. Does surgery belong to medical history for gastric lymphomas? Ann Oncol 1997; 8:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/11\">",
"      Liu HT, Hsu C, Chen CL, et al. Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach. Am J Hematol 2000; 64:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/12\">",
"      Yoon SS, Coit DG, Portlock CS, Karpeh MS. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg 2004; 240:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/13\">",
"      Schmidt WP, Schmitz N, Sonnen R. Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma 2004; 45:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/14\">",
"      Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/15\">",
"      Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995; 122:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/16\">",
"      Bayerd&ouml;rffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/17\">",
"      Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999; 131:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/18\">",
"      Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/19\">",
"      Bertoni F, Conconi A, Capella C, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 2002; 99:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/20\">",
"      W&uuml;ndisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23:8018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/21\">",
"      Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009; 20:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/22\">",
"      Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/23\">",
"      Alpen B, Neubauer A, Dierlamm J, et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 2000; 95:4014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/24\">",
"      Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003; 101:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/25\">",
"      Liu H, Ye H, Dogan A, et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001; 98:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/26\">",
"      Kuo SH, Chen LT, Yeh KH, et al. Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas. J Clin Oncol 2004; 22:3491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/27\">",
"      Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005; 106:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/28\">",
"      Hancock BW, Qian W, Linch D, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 2009; 144:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/29\">",
"      Zullo A, Hassan C, Cristofari F, et al. Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest Oncol 2010; 2:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/30\">",
"      Zucca E, Dreyling M, ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 Suppl 2:ii70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/31\">",
"      Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003; 52:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/32\">",
"      Alpen B, Kuse R, Parwaresch R, et al. Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy. J Clin Oncol 2004; 22:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/33\">",
"      Noy A, Yahalom J, Zaretsky L, et al. Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. J Clin Oncol 2005; 23:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/34\">",
"      Schreuder MI, Hoeve MA, Groothuis L, et al. Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR. Br J Haematol 2005; 131:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/35\">",
"      Fischbach W, Goebeler-Kolve M, Starostik P, et al. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet 2002; 360:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/36\">",
"      Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/37\">",
"      Hitchcock S, Ng AK, Fisher DC, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2002; 52:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/38\">",
"      Tomita N, Kodaira T, Tachibana H, et al. Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother Oncol 2009; 90:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/39\">",
"      Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21:4157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/40\">",
"      Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/41\">",
"      Datta YH, Kampalath B, Binion DG. Rituximab-induced remission of a gastric MALT lymphoma. Leuk Lymphoma 2004; 45:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/42\">",
"      Conconi A, Martinelli G, Thi&eacute;blemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/43\">",
"      Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009; 115:5210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/44\">",
"      Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009; 145:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/45\">",
"      Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/46\">",
"      Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995; 13:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/47\">",
"      L&eacute;vy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005; 23:5061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/48\">",
"      J&auml;ger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002; 20:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/49\">",
"      Streubel B, Ye H, Du MQ, et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004; 66:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/50\">",
"      Conconi A, Martinelli G, Lopez-Guillermo A, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 2011; 22:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/51\">",
"      Raderer M, Streubel B, W&ouml;hrer S, et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/52\">",
"      Nagashima R, Takeda H, Maeda K, et al. Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. Gastroenterology 1996; 111:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/53\">",
"      Matsumoto T, Iida M, Shimizu M. Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori. Lancet 1997; 350:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/54\">",
"      Ben-Ayed F, Halphen M, Najjar T, et al. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group. Cancer 1989; 63:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/55\">",
"      Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/56\">",
"      el Saghir NS, Jessen K, Mass RE, et al. Combination chemotherapy for primary small intestinal lymphoma in the Middle East. Eur J Cancer Clin Oncol 1989; 25:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/57\">",
"      Akbulut H, Soykan I, Yakaryilmaz F, et al. Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Cancer 1997; 80:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/58\">",
"      Taal BG, Boot H, van Heerde P, et al. Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept. Gut 1996; 39:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/59\">",
"      Salles G, Herbrecht R, Tilly H, et al. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs. Am J Med 1991; 90:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/60\">",
"      Gobbi PG, Dionigi P, Barbieri F, et al. The role of surgery in the multimodal treatment of primary gastric non-Hodgkin's lymphomas. A report of 76 cases and review of the literature. Cancer 1990; 65:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/61\">",
"      Maor MH, Velasquez WS, Fuller LM, Silvermintz KB. Stomach conservation in stages IE and IIE gastric non-Hodgkin's lymphoma. J Clin Oncol 1990; 8:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/62\">",
"      Cheung MC, Housri N, Ogilvie MP, et al. Surgery does not adversely affect survival in primary gastrointestinal lymphoma. J Surg Oncol 2009; 100:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/63\">",
"      Kim SJ, Kang HJ, Kim JS, et al. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood 2011; 117:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/64\">",
"      Lai YL, Lin JK, Liang WY, et al. Surgical resection combined with chemotherapy can help achieve better outcomes in patients with primary colonic lymphoma. J Surg Oncol 2011; 104:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/65\">",
"      Avil&eacute;s A, Nambo MJ, Neri N, et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg 2004; 240:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/66\">",
"      Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001; 19:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/67\">",
"      Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001; 19:4245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/68\">",
"      Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood 2012; 119:4838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/69\">",
"      Ferreri AJ, Govi S, Raderer M, et al. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood 2012; 120:3858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/70\">",
"      Ferreri AJ, Cordio S, Ponzoni M, Villa E. Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma. Leuk Lymphoma 1999; 33:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/71\">",
"      Haim N, Leviov M, Ben-Arieh Y, et al. Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy. Leuk Lymphoma 1995; 17:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/72\">",
"      Popescu RA, Wotherspoon AC, Cunningham D, et al. Surgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin's lymphoma: the Royal Marsden Hospital experience. Eur J Cancer 1999; 35:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/73\">",
"      Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005; 23:7050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/74\">",
"      Spectre G, Libster D, Grisariu S, et al. Bleeding, obstruction, and perforation in a series of patients with aggressive gastric lymphoma treated with primary chemotherapy. Ann Surg Oncol 2006; 13:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/75\">",
"      Di Sabatino A, Biagi F, Gobbi PG, Corazza GR. How I treat enteropathy-associated T-cell lymphoma. Blood 2012; 119:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/76\">",
"      Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol 2003; 21:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/77\">",
"      Egan LJ, Walsh SV, Stevens FM, et al. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995; 21:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/78\">",
"      Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000; 18:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/79\">",
"      Okuda M, Nomura J, Tateno H, et al. CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation. Intern Med 2002; 41:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/80\">",
"      Jantunen E, Juvonen E, Wiklund T, et al. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 2003; 44:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/81\">",
"      Bishton MJ, Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 2007; 136:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/82\">",
"      Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010; 115:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/83\">",
"      Halfdanarson TR, Rubio-Tapia A, Ristow KM, et al. Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma. Clin Gastroenterol Hepatol 2010; 8:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/84\">",
"      Lennard A. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma. Br J Haematol 2007; 137:170; author reply 171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/85\">",
"      Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma - response to Lennard. Br J Haematol. 2007; 137:171.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/87\">",
"      Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol 2011; 29:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/88\">",
"      Yoshino T, Miyake K, Ichimura K, et al. Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 2000; 24:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/89\">",
"      Poggi MM, Cong PJ, Coleman CN, Jaffe ES. Low-grade follicular lymphoma of the small intestine. J Clin Gastroenterol 2002; 34:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/90\">",
"      Shia J, Teruya-Feldstein J, Pan D, et al. Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am J Surg Pathol 2002; 26:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/91\">",
"      Bende RJ, Smit LA, Bossenbroek JG, et al. Primary follicular lymphoma of the small intestine: alpha4beta7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B cells. Am J Pathol 2003; 162:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/92\">",
"      Damaj G, Verkarre V, Delmer A, et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol 2003; 14:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/93\">",
"      Sato Y, Ichimura K, Tanaka T, et al. Duodenal follicular lymphomas share common characteristics with mucosa-associated lymphoid tissue lymphomas. J Clin Pathol 2008; 61:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/94\">",
"      Yamamoto S, Nakase H, Yamashita K, et al. Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol 2010; 45:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/53/3930/abstract/95\">",
"      Mori M, Kobayashi Y, Maeshima AM, et al. The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma. Ann Oncol 2010; 21:1500.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4721 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3930=[""].join("\n");
var outline_f3_53_3930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GASTRIC MALT LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Early stage H pylori positive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - H pylori eradication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment failures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Early stage H pylori negative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Restaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Persistent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Advanced stage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NON-GASTRIC MALT LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Non-IPSID non-gastric MALT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immunoproliferative small intestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFUSE LARGE B CELL LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gastric perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ENTEROPATHY-ASSOCIATED T CELL INTESTINAL LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98998264\">",
"      PRIMARY INTESTINAL FOLLICULAR LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANTLE CELL LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      BURKITT LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4721|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/31/33275\" title=\"table 1\">",
"      Lugano staging GI lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/25/39323\" title=\"table 2\">",
"      Grading GI MALT lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17402?source=related_link\">",
"      Initial treatment of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=related_link\">",
"      Treatment of marginal zone (MALT) lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_53_3931="Signs of adrenal crisis";
var content_f3_53_3931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and laboratory findings suggesting adrenal crisis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Dehydration, hypotension, or shock out of proportion to severity of",
"current illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting with a history of weight loss and anorexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain, so-called \"acute abdomen\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyponatremia, hyperkalemia, azotemia, hypercalcemia, or eosinophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperpigmentation or vitiligo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other autoimmune endocrine deficiencies, such as hypothyroidism or gonadal failure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Burke CW. Adrenocortical insufficiency. Clin Endocrinol Metab 1985; 14:947.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3931=[""].join("\n");
var outline_f3_53_3931=null;
var title_f3_53_3932="DSM-IV-TR diagnostic criteria for mania";
var content_f3_53_3932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F81976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F81976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for mania",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood, lasting at least 1 week (or any duration if hospitalization is necessary).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. During the period of mood disturbance, three (or more) of the following symptoms have persisted (four if the mood is only irritable) and have been present to a significant degree:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1) Inflated self-esteem or grandiosity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2) Decreased need for sleep (eg, feels rested after only 3 hours of sleep)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3) More talkative than usual or pressure to keep talking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4) Flight of ideas or subjective experience that thoughts are racing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5) Distractibility (ie, attention too easily drawn to unimportant or irrelevant external stimuli)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6) Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        7) Excessive involvement in pleasurable activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. The symptoms do not meet criteria for a mixed episode.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. The mood disturbance 1) is sufficiently severe to cause marked impairment in occupational functioning, usual social activities, or relationships with others, 2) necessitates hospitalization to prevent harm to self or others, or 3) has psychotic features.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. The symptoms are not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication, or other treatment) or a general medical condition (eg, hyperthyroidism).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3932=[""].join("\n");
var outline_f3_53_3932=null;
var title_f3_53_3933="Post Lyme disease syndrome";
var content_f3_53_3933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed definition of post-Lyme disease syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Inclusion criteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; An adult or child with a documented episode of early or late Lyme disease fulfilling the case definition of the Centers for Disease Control and Prevention. If based on erythema migrans, the diagnosis must be made and documented by an experienced health care practitioner.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; After treatment of the episode of Lyme disease with a generally accepted treatment regimen, there is resolution or stabilization of the objective manifestation(s) of Lyme disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       &bull; Onset of any of the following subjective symptoms within 6 months of the diagnosis of Lyme disease and persistence of continuous or relapsing symptoms for at least a 6 month period after completion of antibiotic therapy:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Fatigue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Widespread musculoskeletal pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Complaints of cognitive difficulties",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Subjective symptoms are of such severity that, when present, they result in substantial reduction in previous levels of occupational, educational, social, or personal activities.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Exclusion criteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; An active, untreated, well-documented coinfection, such as babesiosis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; The presence of objective abnormalities on physical examination or on neuropsychologic testing that may explain the patient's complaints. For example, a patient with antibiotic refractory Lyme arthritis would be excluded. A patient with late neuroborreliosis associated with encephalopathy, who has recurrent or refractory objective cognitive dysfunction, would be excluded.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; A diagnosis of fibromyalgia or chronic fatigue syndrome before the onset of Lyme disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; A prolonged history of undiagnosed or unexplained somatic complaints, such as musculoskeletal pains or fatigue, before the onset of Lyme disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; A diagnosis of an underlying disease or condition that might explain the patient's symptoms (eg, morbid obesity, with a body mass index [calculated as weight in kilograms divided by the square of height in meters] &ge;45; sleep apnea and narcolepsy; side effects of medications; autoimmune diseases; uncontrolled cardiopulmonary or endocrine disorders; malignant conditions within 2 years, except for uncomplicated skin cancer; known current liver disease; any past or current diagnosis of a major depressive disorder with psychotic or melancholic features; bipolar affective disorders; schizophrenia of any subtype; delusional disorders of any subtype; dementias of any subtype; anorexia nervosa or bulimia nervosa; and active drug abuse or alcoholism at present or within 2 years).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Laboratory or imaging abnormalities that might suggest an undiagnosed process distinct from post-Lyme disease syndrome, such as a highly elevated erythrocyte sedimentation rate (&gt;50 mm/hour); abnormal thyroid function; a hematologic abnormality; abnormal levels of serum albumin, total protein, globulin, calcium, phosphorus, glucose, urea nitrogen, electrolytes, or creatinine; significant abnormalities on urine analysis; elevated liver enzyme levels; or a test result suggestive of the presence of a collagen vascular disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Although testing by either culture or PCR for evidence of",
"       <em>",
"        Borrelia burgdorferi",
"       </em>",
"       infection is not required, should such testing be done by reliable methods, a positive result would be an exclusion.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wormser, GP, et al. The clinical assessment, treatment and prevention of Lyme disease, Human Granulocytic Anaplasmosis, and babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089. Copyright &copy;2006 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3933=[""].join("\n");
var outline_f3_53_3933=null;
var title_f3_53_3934="Diastolic BP cardiovascular death HOT trial";
var content_f3_53_3934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diastolic pressure and cardiovascular mortality in HOT trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated incidence (95 percent CI) of cardiovascular mortality in relation to achieved mean diastolic blood pressure in the HOT trial. The diastolic pressure at the lowest point of the curve is indicated (minimum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hansson L, Zanchetti A, Carruthers SG, et al. Lancet 1998; 351:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3934=[""].join("\n");
var outline_f3_53_3934=null;
var title_f3_53_3935="Hamate body fracture xray";
var content_f3_53_3935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hamate body fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This oblique radiograph of the wrist shows a comminuted dorsal hamate body fracture (solid arrows). The base of the 5th metacarpal is indicated by the dotted arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_53_3935=[""].join("\n");
var outline_f3_53_3935=null;
